1
|
Arlet JB, Herquelot E, Lamarsalle L, Raguideau F, Bartolucci P. Impact of hospitalized vaso-occlusive crises in the previous calendar year on mortality and complications in adults with sickle cell disease: a French population-based study. Lancet Reg Health Eur 2024; 40:100901. [PMID: 38596356 PMCID: PMC11002849 DOI: 10.1016/j.lanepe.2024.100901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Revised: 03/25/2024] [Accepted: 03/26/2024] [Indexed: 04/11/2024]
Abstract
Background Historically, sickle cell disease (SCD) patients experiencing frequent hospitalized vaso-occlusive crises (HVOC) have been associated with increased mortality, yet recent data reflecting the widespread use of hydroxyurea and advancements in disease management remain limited. Our study aims to assess the association between HVOC and mortality or severe complications in patients with SCD in this new treatment landscape. Methods This was a retrospective observational cohort study using the French national health data system. Between 01-01-2012 and 12-31-2018, all SCD patients ≥16 years old (ICD-10 codes D57.0-2) were included and followed until 12-31-2018. HVOC was defined as a hospitalization of ≥1 night with primary diagnosis of SCD with crisis, following an emergency room visit. The association between HVOC and severe complications was assessed with a Cox proportional hazards model. Findings In total, 8018 patients (56.6% females; 4538/8018) were included. The 2018 SCD standardized one-year period prevalence was 17.9 cases/100,000 person-years [17.4; 18.3]. The mean rate was 0.84 (1.88) HVOC/person-year. In 2018, 70% (5323/7605), 22% (1671/7605), and 8% (611/7605) of patients experienced 0, 1-2, or 3+ HVOCs, respectively. The median survival time between HVOCs was 415 days [386; 439]. Overall, 312 patients died (3.9%) with a mean age of 49.8 (19.4). Compared to patients without HVOC, the hazard ratios of death in patients with 1-2 or 3+ HVOCs the year prior to death were 1.67 [1.21; 2.30] and 3.70 [2.30; 5.93], respectively. Incidence of acute chest syndrome, pulmonary embolism, osteonecrosis, and sepsis increased with the HVOCs category, but not stroke. In 2018, 29.5% (180/611) of patients with 3+ HVOCs did not take hydroxyurea. Interpretation Patients must be closely monitored during their hospitalizations to intensify treatment and check treatment compliance. Innovative therapies are also required. Funding The study was funded by Novartis.
Collapse
Affiliation(s)
- Jean-Benoît Arlet
- Reference Center for Sickle Cell Disease, Thalassemia and Other Red Blood Cell and Erythropoiesis Diseases, Department of Internal Medicine, Paris-Cité University and European Georges Pompidou University Hospital (AP–HP), 75015, Paris, France
| | | | | | | | - Pablo Bartolucci
- Reference Center for Sickle Cell Disease, Thalassemia and Other Red Blood Cell and Erythropoiesis Diseases, Henri-Mondor Hospital (AP-HP), Créteil, France
| |
Collapse
|
2
|
Razazi K, Berti E, Cecchini J, Carteaux G, Habibi A, Bartolucci P, Arrestier R, Gendreau S, de Prost N, Hulin A, Dessap AM. Decreased risk of underdosing with continuous infusion versus intermittent administration of cefotaxime in patients with sickle cell disease and acute chest syndrome. PLoS One 2024; 19:e0302298. [PMID: 38635540 PMCID: PMC11025818 DOI: 10.1371/journal.pone.0302298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Accepted: 04/01/2024] [Indexed: 04/20/2024] Open
Abstract
OBJECTIVE Underdosing of antibiotics is common in patients with sickle cell disease (SCD). We hypothesized that in critically-ill patients with SCD receiving cefotaxime during acute chest syndrome, the continuous infusion may outperform the intermittent administration in achieving pharmacokinetic/pharmacodynamic targets. DESIGN Prospective before-after study. SETTINGS Intensive-care unit of a French teaching hospital and sickle cell disease referral center. PATIENTS Sixty consecutive episodes of severe acute chest syndrome in 58 adult patients with sickle cell disease. INTERVENTIONS Patients were treated with intermittent administration during the first period (April 2016 -April 2018) and with continuous infusion during the second period (May 2018 -August 2019). MEASUREMENTS AND MAIN RESULTS We included 60 episodes of acute chest syndrome in 58 patients (29 [25-34] years, 37/58 (64%) males). Daily dose of cefotaxime was similar between groups (59 [48-88] vs. 61 [57-64] mg/kg/day, p = 0.84). Most patients (>75%) presented a glomerular hyperfiltration with no difference between groups (p = 0.25). More patients had a cefotaxime trough level ≥2 mg/L with continuous infusion than intermittent administration: 28 (93%) vs. 5 (16%), p<0.001. The median residual concentration was higher in the continuous infusion than intermittent administration group: 10.5 [7.4-13.3] vs. 0 [0-0] mg/L, p<0.001. No infection relapse was observed in the entire cohort. Hospital length of stay was similar between groups. CONCLUSION As compared to intermittent administration, continuous infusion of cefotaxime maximizes the pharmacokinetic/pharmacodynamic parameters in patients with SCD. The clinical outcome did not differ between the two administration methods; however, the study was underpowered to detect such a difference.
Collapse
Affiliation(s)
- Keyvan Razazi
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, F-94010, Créteil, France
- Université Paris Est Créteil, INSERM, IMRB, Créteil, F-94010, France
- Université Paris Est Créteil, CARMAS, Créteil, F-94010, France
| | - Enora Berti
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, F-94010, Créteil, France
- Université Paris Est Créteil, CARMAS, Créteil, F-94010, France
| | - Jerome Cecchini
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, F-94010, Créteil, France
- Université Paris Est Créteil, CARMAS, Créteil, F-94010, France
- Hôpital Intercommunal de Créteil, Service de Réanimation et Surveillance Continue Adulte, 94000, Créteil, France
| | - Guillaume Carteaux
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, F-94010, Créteil, France
- Université Paris Est Créteil, INSERM, IMRB, Créteil, F-94010, France
- Université Paris Est Créteil, CARMAS, Créteil, F-94010, France
| | - Anoosha Habibi
- Université Paris Est Créteil, INSERM, IMRB, Créteil, F-94010, France
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Centre de Référence de la Drépanocytose, Créteil, France
| | - Pablo Bartolucci
- Université Paris Est Créteil, INSERM, IMRB, Créteil, F-94010, France
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Centre de Référence de la Drépanocytose, Créteil, France
| | - Romain Arrestier
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, F-94010, Créteil, France
- Université Paris Est Créteil, INSERM, IMRB, Créteil, F-94010, France
- Université Paris Est Créteil, CARMAS, Créteil, F-94010, France
| | - Ségolène Gendreau
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, F-94010, Créteil, France
- Université Paris Est Créteil, INSERM, IMRB, Créteil, F-94010, France
- Université Paris Est Créteil, CARMAS, Créteil, F-94010, France
| | - Nicolas de Prost
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, F-94010, Créteil, France
- Université Paris Est Créteil, INSERM, IMRB, Créteil, F-94010, France
- Université Paris Est Créteil, CARMAS, Créteil, F-94010, France
| | - Anne Hulin
- AP-HP, Hôpitaux Universitaires Henri Mondor, Service de Biochimie, Créteil, 94010 France
| | - Armand Mekontso Dessap
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, F-94010, Créteil, France
- Université Paris Est Créteil, INSERM, IMRB, Créteil, F-94010, France
- Université Paris Est Créteil, CARMAS, Créteil, F-94010, France
| |
Collapse
|
3
|
Mougin L, Riccetti M, Merlet AN, Bartolucci P, Gellen B, Blervaque L, D'Humières T, Galactéros F, Emhoff CAW, Féasson L, Messonnier LA. Endurance training improves oxygen uptake/demand mismatch, metabolic flexibility and recovery in patients with sickle cell disease. Haematologica 2024. [PMID: 38572551 DOI: 10.3324/haematol.2023.284474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Indexed: 04/05/2024] Open
Abstract
Patients with sickle cell disease (SCD) display lower slope coefficients of the oxygen uptake (V_O2) vs. work rate (W) relationship (delineating an O2 uptake/demand mismatch) and a poor metabolic flexibility. Because endurance training (ET) increases the microvascular network and oxidative enzymes activity including one involved in lipid oxidation, ET might improve the slope coefficient of the V_O2 vs. W curve and the metabolic flexibility of SCD patients. ET may also contribute to improve patient post-exercise cardiopulmonary and metabolic recovery. Fifteen patients with SCD performed a submaximal incremental test on a cycle ergometer before (SIT1) and after (SIT2) 8 weeks of ET. Minute ventilation, ventilation rate (VR), heart rate (HR), V_O2, CO2 production, respiratory exchange ratio, carbohydrate/lipid utilization and partitioning (including %Lipidox) and blood lactate concentration ([lactate]b) were measured during and after SIT1 and SIT2. At baseline, the slope coefficient of the V_O2 vs. W curve positively correlated with total hemoglobin, mean corpuscular hemoglobin and percentage of HbF. After training, the slope coefficient of the V_O2 vs. W curve was significantly higher and the [lactate]b increase was delayed. If patients' energy metabolism apparently relied largely on carbohydrate sources during SIT1, %Lipidox tended to increase at low exercise intensities during SIT2, supporting a training-induced improvement of metabolic flexibility in patients with SCD. Post-exercise recovery of VR, V_E/V_CO2, HR and [lactate]b was faster after training. We concluded that ET in patients with SCD i) ameliorated the oxygen uptake/demand mismatch, ii) blunted the metabolic inflexibility, and iii) improved post-exercise cardiopulmonary and metabolic responses.
Collapse
Affiliation(s)
- Loïs Mougin
- Inter-university Laboratory of Human Movement Sciences, University Savoie Mont Blanc, Chambéry
| | - Manon Riccetti
- Inter-university Laboratory of Human Movement Sciences, University Savoie Mont Blanc, Chambéry
| | - Angèle N Merlet
- Inter-university Laboratory of Human Movement Sciences, University Jean Monnet, Saint-Etienne, France; Myology Unit, Department of Clinical Physiology and Exercise, Saint-Etienne University Hospital, Saint-Etienne
| | - Pablo Bartolucci
- Department of Internal Medicine, Henri-Mondor Hospital (AP-HP), University Paris-Est Créteil (UPEC), Créteil, France; Sickle Cell Referral Centre - UMGGR, Great Paris East Rare Diseases Expertise Platform, UPEC, FHU SENEC, Henri-Mondor Hospital (AP-HP), Créteil
| | - Barnabas Gellen
- Department of Cardiac Rehabilitation, Henri-Mondor Hospital (AP-HP), Créteil
| | - Léo Blervaque
- Inter-university Laboratory of Human Movement Sciences, University Savoie Mont Blanc, Chambéry
| | - Thomas D'Humières
- Sickle Cell Referral Centre - UMGGR, Great Paris East Rare Diseases Expertise Platform, UPEC, FHU SENEC, Henri-Mondor Hospital (AP-HP), Créteil, France; Department of Physiology, FHU SENEC, Henri-Mondor Hospital (AP-HP), Créteil, France; INSERM IMRB U955, Team 8, University Paris Est (UPEC), Créteil
| | - Frédéric Galactéros
- Department of Internal Medicine, Henri-Mondor Hospital (AP-HP), University Paris-Est Créteil (UPEC), Créteil, France; Sickle Cell Referral Centre - UMGGR, Great Paris East Rare Diseases Expertise Platform, UPEC, FHU SENEC, Henri-Mondor Hospital (AP-HP), Créteil
| | - Chi-An W Emhoff
- Inter-university Laboratory of Human Movement Sciences, University Savoie Mont Blanc, Chambéry, France; Department of Kinesiology, Saint Mary's College of California, Moraga, California
| | - Léonard Féasson
- Inter-university Laboratory of Human Movement Sciences, University Jean Monnet, Saint-Etienne, France; Myology Unit, Department of Clinical Physiology and Exercise, Saint-Etienne University Hospital, Saint-Etienne
| | - Laurent A Messonnier
- Inter-university Laboratory of Human Movement Sciences, University Savoie Mont Blanc, Chambéry, France; Institut universitaire de France (IUF).
| |
Collapse
|
4
|
Nguyen KA, Matte A, Foresti R, Federti E, Kiger L, Lefebvre C, Hocini H, Pelinski Y, Kitagishi H, Bencheikh L, Pirenne F, De Franceschi L, Motterlini R, Bartolucci P. An Oral Carbon Monoxide-Releasing Molecule Protects against Acute Hyper-hemolysis in Sickle Cell Disease. Blood 2024:blood.2023023165. [PMID: 38518106 DOI: 10.1182/blood.2023023165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 03/06/2024] [Accepted: 03/17/2024] [Indexed: 03/24/2024] Open
Abstract
Acute hyper-hemolysis is a severe life-threatening complication in patients with sickle cell disease (SCD) that may occur during delayed hemolytic transfusion reaction (DHTR), or vaso-occlusive crises associated with multi-organ failure. Here, we developed in vitro and in vivo animal models to mimic endothelial damage during the early phase of hyper-hemolysis in SCD. We then used the carbon monoxide (CO)-releasing molecule CORM-401 and examined its effects against endothelial activation, damage, and inflammation inflicted by hemolysates containing red blood cell membrane-derived particles. The in vitro results revealed that CORM-401: 1) prevented the up-regulation of relevant pro-inflammatory, and pro-adhesion controlled by the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and 2) abolished the expression of the nuclear factor erythroid-2-related factor 2 (Nrf2) that regulates the inducible antioxidant cell machinery. We also show in SCD mice that CORM-401 protects against hemolysate-induced acute damage of target organs such as the lung, liver, and kidney through modulation of NF-kB pro-inflammatory and Nrf2 antioxidant pathways. Our data demonstrate the efficacy of CORM-401 as a novel therapeutic agent to counteract hemolysate-induced organ damage during hyper-hemolysis in SCD. This approach might be considered as possible preventive treatment in high-risk situations such as SCD patients with history of DHTR.
Collapse
Affiliation(s)
- Kim Anh Nguyen
- Etablissement Français du Sang, Île-de-France Mondor; Laboraroire d'Excellence, INSERM U955, IMRB, Team Pirenne, Créteil, France
| | - Alessandro Matte
- Dept of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
| | - Roberta Foresti
- University Paris-Est Créteil, INSERM, IMRB, F-94010, Créteil, France
| | - Enrica Federti
- Dept of Engineering for innovative medicine -DIMI , University of Verona and Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
| | | | | | | | | | | | | | - France Pirenne
- University Paris Est Créteil, INSERM U955, Etablissement Francais du Sang, Creteil, France
| | | | | | | |
Collapse
|
5
|
Abdulrehman J, Forté S, Tomlinson G, Solh Z, Bolster L, Sun HL, Bartolucci P, Kuo KHM. THromboprophylaxis In Sickle Cell Disease with central venous catheters (THIS): an internal pilot randomised controlled trial protocol. BMJ Open 2024; 14:e079363. [PMID: 38171625 PMCID: PMC10773310 DOI: 10.1136/bmjopen-2023-079363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Accepted: 11/29/2023] [Indexed: 01/05/2024] Open
Abstract
INTRODUCTION Individuals with sickle cell disease (SCD) and central venous catheters (CVC) are at high risk for venous thromboembolism (VTE). Minimal data exist regarding the use of anticoagulation as thromboprophylaxis of VTE in this demographic, and as a result, clinical equipoise exists. Prophylactic dose rivaroxaban, a direct oral anticoagulant, is efficacious and safe as thromboprophylaxis in other demographics, and may be an optimal agent in SCD with CVC. Prior to conducting a full clinical trial to assess rivaroxaban as thromboprophylaxis in SCD with CVC, a pilot study is needed to gauge its feasibility. METHODS AND ANALYSIS THromboprophylaxis In Sickle Cell Disease pilot trial is an investigator-initiated, multicentre, double-blinded, randomised controlled trial (RCT) assessing if it is feasible and safe to conduct an adequately powered RCT comparing rivaroxaban to matching placebo as thromboprophylaxis in those with SCD and CVC. Fifty adult patients with SCD and CVC will be randomised to receive either rivaroxaban 10 mg daily or matching placebo for the duration of the CVC in situ for up to 1 year. After randomisation, follow-up visits will occur every 3 months. The primary outcomes pertain to the feasibility of a full trial and include numbers of eligible and recruited participants. Exploratory outcomes include overall incidence of VTE and bleeding complications, as well as quality of life. If the full trial is feasible, blinding will be maintained and patients in the pilot study will be included in the full trial. ETHICS AND DISSEMINATION The trial was initially approved by the University Health Network Research Ethics Board (REB) in Toronto, Canada. All sites will obtain approval from their respective REB prior to commencement of study activities. Study results will be disseminated through presentations at medical conferences and peer-reviewed publications. TRIAL REGISTRATION NUMBER NCT05033314.
Collapse
Affiliation(s)
- Jameel Abdulrehman
- Division of Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Stephanie Forté
- Division of Hematology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Québec, Canada
| | - George Tomlinson
- Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Ziad Solh
- Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
- Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Lauren Bolster
- Division of Hematology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Haowei Linda Sun
- Division of Hematology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Pablo Bartolucci
- Department of Internal Medicine, Assistance Publique Hopitaux de Paris, Creteil, France
| | - Kevin H M Kuo
- Division of Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
6
|
Baron C, Cherkaoui S, Therrien-Laperriere S, Ilboudo Y, Poujol R, Mehanna P, Garrett ME, Telen MJ, Ashley-Koch AE, Bartolucci P, Rioux JD, Lettre G, Rosiers CD, Ruiz M, Hussin JG. Gene-metabolite annotation with shortest reactional distance enhances metabolite genome-wide association studies results. iScience 2023; 26:108473. [PMID: 38077122 PMCID: PMC10709128 DOI: 10.1016/j.isci.2023.108473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 08/24/2023] [Accepted: 11/13/2023] [Indexed: 12/20/2023] Open
Abstract
Metabolite genome-wide association studies (mGWAS) have advanced our understanding of the genetic control of metabolite levels. However, interpreting these associations remains challenging due to a lack of tools to annotate gene-metabolite pairs beyond the use of conservative statistical significance threshold. Here, we introduce the shortest reactional distance (SRD) metric, drawing from the comprehensive KEGG database, to enhance the biological interpretation of mGWAS results. We applied this approach to three independent mGWAS, including a case study on sickle cell disease patients. Our analysis reveals an enrichment of small SRD values in reported mGWAS pairs, with SRD values significantly correlating with mGWAS p values, even beyond the standard conservative thresholds. We demonstrate the utility of SRD annotation in identifying potential false negatives and inaccuracies within current metabolic pathway databases. Our findings highlight the SRD metric as an objective, quantitative and easy-to-compute annotation for gene-metabolite pairs, suitable to integrate statistical evidence to biological networks.
Collapse
Affiliation(s)
- Cantin Baron
- Département de Biochimie et de Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada
- Montreal Heart Institute, Montréal, QC, Canada
| | - Sarah Cherkaoui
- Montreal Heart Institute, Montréal, QC, Canada
- Division of Oncology and Children’s Research Center, University Children’s Hospital Zurich, University of Zurich, Zurich, Switzerland
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France
| | | | - Yann Ilboudo
- Département de Biochimie et de Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada
- Montreal Heart Institute, Montréal, QC, Canada
| | | | | | - Melanie E. Garrett
- Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, USA
| | - Marilyn J. Telen
- Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
| | | | - Pablo Bartolucci
- Université Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, Sickle cell referral center – UMGGR, Créteil, France
- Université Paris Est Créteil, IMRB, Laboratory of excellence LABEX, Créteil, France
| | - John D. Rioux
- Département de Biochimie et de Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada
- Montreal Heart Institute, Montréal, QC, Canada
- Département de Médecine, Université de Montréal, Montréal, QC, Canada
| | - Guillaume Lettre
- Montreal Heart Institute, Montréal, QC, Canada
- Département de Médecine, Université de Montréal, Montréal, QC, Canada
| | - Christine Des Rosiers
- Département de Biochimie et de Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada
- Montreal Heart Institute, Montréal, QC, Canada
- Département de Nutrition, Université de Montréal, Montréal, QC, Canada
| | - Matthieu Ruiz
- Montreal Heart Institute, Montréal, QC, Canada
- Département de Nutrition, Université de Montréal, Montréal, QC, Canada
| | - Julie G. Hussin
- Montreal Heart Institute, Montréal, QC, Canada
- Département de Médecine, Université de Montréal, Montréal, QC, Canada
| |
Collapse
|
7
|
Duvoux C, Blaise L, Matimbo JJ, Mubenga F, Ngongang N, Hurtova M, Laurent A, Augustin J, Calderaro J, Reizine E, Luciani A, Habibi A, Bachir D, Vole G, Gellen-Dautremer J, Leroy V, Levesque E, Bartolucci P. The liver in sickle cell disease. Presse Med 2023; 52:104212. [PMID: 37981193 DOI: 10.1016/j.lpm.2023.104212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2023] Open
Abstract
Liver involvement in SCD patients is frequent but often misdiagnosed or underestimated, except in case of advanced liver diseases. Because of so far poorly recognized forms of chronic SCD-related vascular injury that can silently evolved towards end stages or facilitate ACLF, any persisting liver function tests abnormalities should be carefully investigated, following the above proposed algorithm. Work up and management must be considered multidisciplinary in relationship with a Hepatologist. Early SCD hepatopathy should prompt revision of SCD management to prevent further liver injury and decompensation, discussing transfusion exchanges and hydro urea when not yet initiated, and control for any cofactor of liver injury. The role of HSCT in early SCD hepatopathies also deserves evaluation. In advanced SCD hepatopathies, liver transplantation, which has been rarely performed so far, is the only therapeutic option associated with improved survival. It should definitely be discussed- either electively in case of decompensation in SCD cirrhosis or jaundice/recurrent cholangitis in cholestatic diseases, with excellent outcome, - or emergently in case of ALF or ACLF with more mitigate results. To improve knowledge and management of SCD liver diseases, creation of national and international registries, as well as longitudinal observational cohorts are encouraged.
Collapse
Affiliation(s)
- Christophe Duvoux
- Department of Hepatology and Medical Liver Transplant Unit, Henri Mondor Hospital-APHP, University Paris Est Créteil, France.
| | - Lorraine Blaise
- Department of Hepatology and Liver Oncology, Avicenne Hospital-APHP, Bobigny, France
| | - Jean-Jacques Matimbo
- Department of Hepatology and Medical Liver Transplant Unit, Henri Mondor Hospital-APHP, University Paris Est Créteil, France; Department of Hepatology and Liver Oncology, Avicenne Hospital-APHP, Bobigny, France; Department of Hepatology and Gastroenterology, Clinique Universitaire Kinshasa, Democratic Republic of Congo
| | | | - Norbert Ngongang
- Department of Hepatology and Medical Liver Transplant Unit, Henri Mondor Hospital-APHP, University Paris Est Créteil, France
| | - Monika Hurtova
- Department of Hepatology and Medical Liver Transplant Unit, Henri Mondor Hospital-APHP, University Paris Est Créteil, France
| | - Alexis Laurent
- Department of Digestive & HPB Surgery, Henri Mondor Hospital-APHP, University Paris Est Créteil, France
| | - Jérémy Augustin
- Department of Pathology, Henri Mondor Hospital-APHP, University Paris Est Créteil, France
| | - Julien Calderaro
- Department of Pathology, Henri Mondor Hospital-APHP, University Paris Est Créteil, France
| | - Edouard Reizine
- Department of Radiology, Henri Mondor Hospital-APHP, University Paris Est Créteil, France
| | - Alain Luciani
- Department of Radiology, Henri Mondor Hospital-APHP, University Paris Est Créteil, France
| | - Anoosha Habibi
- UMGGR, Department of Internal Medicine, Sickle Cell National Referral Center, Henri Mondor-Hospital APHP, University Paris Est Créteil, France; IMRB, UPEC, INSERM, EFS, Team Pirenne. University Paris Est Créteil, France
| | - Dora Bachir
- UMGGR, Department of Internal Medicine, Sickle Cell National Referral Center, Henri Mondor-Hospital APHP, University Paris Est Créteil, France
| | - Geoffroy Vole
- UMGGR, Department of Internal Medicine, Sickle Cell National Referral Center, Henri Mondor-Hospital APHP, University Paris Est Créteil, France; IMRB, UPEC, INSERM, EFS, Team Pirenne. University Paris Est Créteil, France
| | | | - Vincent Leroy
- Department of Hepatology and Medical Liver Transplant Unit, Henri Mondor Hospital-APHP, University Paris Est Créteil, France
| | - Eric Levesque
- Department of Anesthesia and Surgical Intensive Care-liver ICU, Henri Mondor Hospital-APHP, University Paris Est Créteil, France
| | - Pablo Bartolucci
- UMGGR, Department of Internal Medicine, Sickle Cell National Referral Center, Henri Mondor-Hospital APHP, University Paris Est Créteil, France; IMRB, UPEC, INSERM, EFS, Team Pirenne. University Paris Est Créteil, France
| |
Collapse
|
8
|
Affiliation(s)
- Pablo Bartolucci
- Univ Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, Sickle cell and Red cell disorders referral center - UMGGR, Créteil, France; IMRB, Laboratory of excellence LABEX GRex, Créteil, France; Clinical Investigation Center, 1430, France.
| |
Collapse
|
9
|
Couette M, Roy J, Doglioni DO, Bereznyakova O, Stapf C, Jacquin G, Fraïle V, Desmarais P, Desforges SM, Touma L, Nauche B, Bartolucci P, Kuo KHM, Forté S. Screening for cognitive impairment in adults with sickle cell disease: A systematic review and meta-analysis. Presse Med 2023; 52:104207. [PMID: 37979834 DOI: 10.1016/j.lpm.2023.104207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Accepted: 10/29/2023] [Indexed: 11/20/2023] Open
Abstract
Neurovascular disease such as symptomatic stroke, silent brain infarcts and vascular cognitive impairment are common complications of sickle cell disease (SCD) that can have devastating consequences on quality of life, employment, and social functioning. Early recognition of neurovascular disease is a prerequisite for the timely optimization of medical care and to connect patients to adaptive resources. While cognitive impairment has been well described in children, currently available data are limited in adults. As a result, guidance on the optimal cognitive screening strategies in adults is scarce. We conducted a systematic review to identify the different screening tools that have been evaluated in SCD. A meta-analysis was performed to estimate the prevalence of suspected cognitive impairment in this population. In this qualitative synthesis, we present 8 studies that evaluated 6 different screening tools. Patient characteristics that impacted on cognitive screening performance included age, education level, and a prior history of stroke. We report a pooled prevalence of 38% [14-62%] of suspected cognitive impairment. We discuss the relative benefits and limitations of the different screening tools to help clinicians select an adapted approach tailored to their specific patients' needs. Further studies are needed to establish and validate cognitive screening strategies in patients with diverse cultural and educational backgrounds.
Collapse
Affiliation(s)
- Maryline Couette
- Sickle Cell Referral Centre-UMGGR, University of Paris Est Créteil, Henri Mondor APHP, 94010, Créteil, France; CARMAS (Cardiovascular and Respiratory Manifestations of Acute Lung Injury and Sepsis), University of Paris Est Créteil, 94010, Créteil, France; IMRB, INSERM, University of Paris Est Créteil, 94010, Créteil, France
| | - Justine Roy
- Faculté de médecine, Université de Montréal, Montréal, QC, H3C 3J7, Canada
| | - Damien Oudin Doglioni
- Sickle Cell Referral Centre-UMGGR, University of Paris Est Créteil, Henri Mondor APHP, 94010, Créteil, France; Laboratoire Inter-Universitaire de Psychologie-Personnalité, Cognition, Changement Social (LIP/PC2S), Université Grenoble Alpes, 38058, Saint-Martin-d'Hères, France
| | - Olena Bereznyakova
- Axe Neurosciences et Carrefour de l'innovation, Centre de Recherche du CHUM (CRCHUM), Montréal, QC, H2X 0A9, Canada; Division of Neurology, Department of Medicine, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, QC, H2X 0C1, Canada; Department of Neurosciences, Université de Montréal, Montréal, QC, H3C 3J7, Canada
| | - Christian Stapf
- Axe Neurosciences et Carrefour de l'innovation, Centre de Recherche du CHUM (CRCHUM), Montréal, QC, H2X 0A9, Canada; Division of Neurology, Department of Medicine, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, QC, H2X 0C1, Canada; Department of Neurosciences, Université de Montréal, Montréal, QC, H3C 3J7, Canada
| | - Gregory Jacquin
- Axe Neurosciences et Carrefour de l'innovation, Centre de Recherche du CHUM (CRCHUM), Montréal, QC, H2X 0A9, Canada; Division of Neurology, Department of Medicine, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, QC, H2X 0C1, Canada; Department of Neurosciences, Université de Montréal, Montréal, QC, H3C 3J7, Canada
| | - Valérie Fraïle
- Division of Psychology, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, QC, H2X 0C1, Canada
| | - Philippe Desmarais
- Axe Neurosciences et Carrefour de l'innovation, Centre de Recherche du CHUM (CRCHUM), Montréal, QC, H2X 0A9, Canada; Department of Neurosciences, Université de Montréal, Montréal, QC, H3C 3J7, Canada; Division of Geriatrics, Department of Medicine, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, QC, H2X 0C1, Canada
| | - Sara-Maude Desforges
- Faculté de médecine, Université de Montréal, Montréal, QC, H3C 3J7, Canada; Department of Medecine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, H2X 0C1, Canada
| | - Lahoud Touma
- Division of Neurology, Department of Medicine, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, QC, H2X 0C1, Canada; Department of Neurosciences, Université de Montréal, Montréal, QC, H3C 3J7, Canada
| | - Bénédicte Nauche
- Library, Centre Hospitalier de l'Université de Montréal, Montréal, QC, H2X 3E4, Canada
| | - Pablo Bartolucci
- Sickle Cell Referral Centre-UMGGR, University of Paris Est Créteil, Henri Mondor APHP, 94010, Créteil, France; IMRB, INSERM, University of Paris Est Créteil, 94010, Créteil, France; INSERM-U955, Equipe 2, Laboratoire d'Excellence, GRex, Institut Mondor, 94000, Créteil, France
| | - Kevin H M Kuo
- Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, M5S 1A1, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, ON, M5G 2N2, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, M5T 3M7, Canada
| | - Stéphanie Forté
- Faculté de médecine, Université de Montréal, Montréal, QC, H3C 3J7, Canada; Department of Medicine, Division of Hematology and Medical Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, H2X 3E4, Canada; Carrefour de l'innovation, Centre de Recherche du CHUM (CRCHUM), Montréal, H2X 0A9, QC, Canada.
| |
Collapse
|
10
|
Sobczyk O, Gottardi E, Lefebvre M, Canouï-Poitrine F, Jebali A, De Luna G, Pirenne F, Redel D, Galacteros F, Boutin E, Bartolucci P, Haddad B, Habibi A, Lecarpentier E. Evaluation of a prophylactic transfusion program on obstetric outcomes in pregnant women with sickle cell disease: A single centre retrospective cohort study. Eur J Obstet Gynecol Reprod Biol 2023; 290:103-108. [PMID: 37776703 DOI: 10.1016/j.ejogrb.2023.08.390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 08/04/2023] [Accepted: 08/30/2023] [Indexed: 10/02/2023]
Abstract
OBJECTIVE To evaluate the effects of a prophylactic transfusion program (TP) on obstetric and perinatal outcomes in pregnant women with sickle cell disease (SCD). METHODS This retrospective cohort study included all singleton pregnancies among women with SCD in a French university tertiary care center between 1 January 2004 and 31 December 2017. The TP group included patients selected according to the French guidelines who received regular red blood cell transfusions during pregnancy until delivery. The factors associated with TP indication [year of birth, SCD genotype, history of acute chest syndrome and delayed hemolysis transfusion reaction (DHTR) risk score] were taken into account in a propensity score. A composite obstetric adverse outcome was defined associating birth before 34 gestational weeks and/or pre-eclampsia and/or small for gestational age and/or abruption and/or stillbirth and/or maternal death and/or neonatal death. RESULTS In total, 246 pregnancies in 173 patients were analyzed. Twenty-two pregnancies with a history of DHTR were excluded. A higher frequency of TP was found before 2013 [119/148 (80.4%) vs 38/76 (50%); p < 0.001]. Rates of preterm birth before 34 gestational weeks (5.6% vs 19.7%; p = 0.001), vaso-occlusive crisis (36.5% vs. 61.8%; p < 0.001), and acute chest syndrome (6.1% vs. 14.5%; p = 0.04) during pregnancy were decreased significantly in the TP group. Among the groups with and without composite obstetric adverse outcomes, the frequency of TP was 52.6% and 74.7%, respectively [odds ratio (OR) 0.30, 95% confidence interval (CI) 0.09-1.02]. The multivariate analysis shows that the TP was associated with a significant reduction in the risk of composite obstetric adverse outcomes (OR 0.28, 95% CI 0.08-0.97; p = 0.04). CONCLUSION A red blood cell TP may have an independent protective effect on maternal and perinatal adverse outcomes during pregnancy in women with SCD.
Collapse
Affiliation(s)
- O Sobczyk
- Service de Gynécologie Obstétrique, Centre Hospitalier Intercommunal de Créteil, France; Univ Paris Est Créteil, France
| | - E Gottardi
- Service de Gynécologie Obstétrique, Centre Hospitalier Intercommunal de Créteil, France; Univ Paris Est Créteil, France
| | - M Lefebvre
- Service de Gynécologie Obstétrique, Centre Hospitalier Intercommunal de Créteil, France; Univ Paris Est Créteil, France
| | - F Canouï-Poitrine
- Univ Paris Est Créteil, France; Département de Santé Publique et de Biostatistiques de l'Hôpital Henri Mondo, France; Unité de Recherche Clinique de l'Hôpital Henri Mondor, France
| | - A Jebali
- Sickle Cell Referral Center, Henri Mondor Hospital, AP-HP, Creteil, France
| | - G De Luna
- Sickle Cell Referral Center, Henri Mondor Hospital, AP-HP, Creteil, France
| | - F Pirenne
- Univ Paris Est Créteil, France; Laboratory of Excellence GR-Ex, INSERM Unit 955, Mondor Institute of Biomedical Research, Paris-Est Creteil University, Creteil, France; Établissement Français du Sang Ile de France, Créteil, France
| | - D Redel
- Service de Gynécologie Obstétrique, Centre Hospitalier Intercommunal de Créteil, France; Centre de recherche clinique du CHI Créteil, France
| | - F Galacteros
- Sickle Cell Referral Center, Henri Mondor Hospital, AP-HP, Creteil, France; Laboratory of Excellence GR-Ex, INSERM Unit 955, Mondor Institute of Biomedical Research, Paris-Est Creteil University, Creteil, France
| | - E Boutin
- Département de Santé Publique et de Biostatistiques de l'Hôpital Henri Mondo, France; Unité de Recherche Clinique de l'Hôpital Henri Mondor, France
| | - P Bartolucci
- Univ Paris Est Créteil, France; Sickle Cell Referral Center, Henri Mondor Hospital, AP-HP, Creteil, France; Laboratory of Excellence GR-Ex, INSERM Unit 955, Mondor Institute of Biomedical Research, Paris-Est Creteil University, Creteil, France
| | - B Haddad
- Service de Gynécologie Obstétrique, Centre Hospitalier Intercommunal de Créteil, France; Univ Paris Est Créteil, France; INSERM, IMRB U955 I-BIOT, 94010 Créteil, France
| | - A Habibi
- Univ Paris Est Créteil, France; Sickle Cell Referral Center, Henri Mondor Hospital, AP-HP, Creteil, France; Laboratory of Excellence GR-Ex, INSERM Unit 955, Mondor Institute of Biomedical Research, Paris-Est Creteil University, Creteil, France
| | - E Lecarpentier
- Service de Gynécologie Obstétrique, Centre Hospitalier Intercommunal de Créteil, France; Univ Paris Est Créteil, France; INSERM, IMRB U955 I-BIOT, 94010 Créteil, France.
| |
Collapse
|
11
|
Bartolucci P. Exploration de l’hémolyse associée à la drépanocytose et perspectives thérapeutiques spécifiques. Rev Med Interne 2023; 44:4S7-4S11. [PMID: 38049244 DOI: 10.1016/s0248-8663(23)01303-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/06/2023]
Abstract
Sickle Cell Anemia is a disease with a strong vascular tropism. Beyond anemia, the pathophysiological mechanisms responsible for hemolysis, directly affect both acute and chronic vascular damages, thus resulting in a systemic disease. Understanding the different types of hemolysis underline the need for novel specific biomarkers. Targeted therapeutic approaches for these pathophysiological pathways are necessary to improve Sickle Cell patients' prognosis. Finally, given its complexity, Sickle Cell Disease is often used as a "proof of concept" for other pathologies. It seems likely that the rapidly evolving knowledge in this field will also benefit other diseases. © 2023 Société nationale française de médecine interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
Collapse
Affiliation(s)
- P Bartolucci
- Recherche IH, EFS Créteil-Mondor, Créteil, France; IMRB Inserm 955, équipe Pirenne, Créteil, France; Centre de références des syndromes drépanocytaires majeures, hôpital Henri-Mondor, Créteil, France; Université Paris-Est Créteil, Créteil, France.
| |
Collapse
|
12
|
De Souza DC, Hebert N, Esrick EB, Ciuculescu MF, Archer NM, Armant M, Audureau É, Brendel C, Di Caprio G, Galactéros F, Liu D, McCabe A, Morris E, Schonbrun E, Williams D, Wood DK, Williams DA, Bartolucci P, Higgins JM. Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling. Nat Commun 2023; 14:5850. [PMID: 37730674 PMCID: PMC10511721 DOI: 10.1038/s41467-023-40923-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 08/14/2023] [Indexed: 09/22/2023] Open
Abstract
We previously reported initial clinical results of post-transcriptional gene silencing of BCL11A expression (NCT03282656) reversing the fetal to adult hemoglobin switch. A goal of this approach is to increase fetal hemoglobin (HbF) expression while coordinately reducing sickle hemoglobin (HbS) expression. The resulting combinatorial effect should prove effective in inhibiting HbS polymerization at lower physiologic oxygen values thereby mitigating disease complications. Here we report results of exploratory single-cell analysis of patients in which BCL11A is targeted molecularly and compare results with cells of patients treated with hydroxyurea (HU), the current standard of care. We use single-cell assays to assess HbF, HbS, oxygen saturation, and hemoglobin polymer content in RBCs for nine gene therapy trial subjects (BCLshmiR, median HbF% = 27.9) and compare them to 10 HU-treated subjects demonstrating high and comparable levels of HbF (HU High Responders, median HbF% = 27.0). All BCL11A patients achieved the primary endpoint for NCT03282656, which was defined by an absolute neutrophil count greater than or equal to 0.5 × 109 cells/L for three consecutive days, achieved within 7 weeks following infusion. Flow cytometric assessment of single-RBC HbF and HbS shows fewer RBCs with high HbS% that would be most susceptible to sickling in BCLshmiR vs. HU High Responders: median 42% of RBCs with HbS%>70% in BCLshmiR vs. 61% in HU High Responders (p = 0.004). BCLshmiR subjects also demonstrate more RBCs resistant to HbS polymerization at lower physiologic oxygen tension: median 32% vs. 25% in HU High Responders (p = 0.006). Gene therapy-induced BCL11A down-regulation reverses the fetal-to-adult hemoglobin switch and induces RBCs with higher HbF%, lower HbS%, and greater resistance to deoxygenation-induced polymerization in clinical trial subjects compared with a cohort of highly responsive hydroxyurea-treated subjects.
Collapse
Affiliation(s)
- Daniel C De Souza
- Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA
- Department of Systems Biology, Harvard Medical School, Boston, MA, USA
- Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
| | - Nicolas Hebert
- French Blood Establishment (EFS), Créteil, France
- University Paris-Est-Créteil, IMRB, Laboratory of excellence LABEX, Créteil, France
- Paris-East Créteil University, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center-UMGGR, Créteil, France
| | - Erica B Esrick
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Department of Pediatrics, Harvard Medical School, Boston, MA, USA
| | | | - Natasha M Archer
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Department of Pediatrics, Harvard Medical School, Boston, MA, USA
| | - Myriam Armant
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Étienne Audureau
- INSERM U955 Team CEpiA, Paris-East Créteil University, Créteil, France
- Department of Public Health, Henri Mondor University Hospitals, APHP, Créteil, France
| | - Christian Brendel
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Department of Pediatrics, Harvard Medical School, Boston, MA, USA
| | - Giuseppe Di Caprio
- Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA
- Department of Pediatrics, Harvard Medical School, Boston, MA, USA
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA
- Department of Biomedical Engineering, University of Strathclyde, Glasgow, United Kingdom
| | - Frédéric Galactéros
- University Paris-Est-Créteil, IMRB, Laboratory of excellence LABEX, Créteil, France
- Paris-East Créteil University, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center-UMGGR, Créteil, France
| | - Donghui Liu
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Amanda McCabe
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Emily Morris
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Ethan Schonbrun
- Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Dillon Williams
- Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA
| | - David K Wood
- Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA
| | - David A Williams
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
| | - Pablo Bartolucci
- University Paris-Est-Créteil, IMRB, Laboratory of excellence LABEX, Créteil, France.
- Paris-East Créteil University, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center-UMGGR, Créteil, France.
| | - John M Higgins
- Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
- Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
- Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
| |
Collapse
|
13
|
d'Humières T, Saba J, Savale L, Dupuy M, Boyer L, Guillet H, Alassaad L, de Luna G, Iles S, Pham Hung d'Alexandry d'Orengiani AL, Zaouali Y, Boukour N, Pelinski Y, Messonnier L, Audureau E, Derbel H, Habibi A, Lellouche N, Derumeaux G, Bartolucci P. Determinants of ventricular arrhythmias in sickle cell anemia: toward better prevention of sudden cardiac death. Blood 2023; 142:409-420. [PMID: 37216685 DOI: 10.1182/blood.2022019571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Revised: 05/09/2023] [Accepted: 05/10/2023] [Indexed: 05/24/2023] Open
Abstract
Sudden death is 1 of the leading causes of death in adults with sickle cell anemia (SCA) but its etiology remains mostly unknown. Ventricular arrhythmia (VA) carries an increased risk of sudden death; however, its prevalence and determinants in SCA are poorly studied. This study aimed to identify the prevalence and predictors of VA in patients with SCA. From 2019 to 2022, 100 patients with SCA were referred to the physiology department to specifically analyze cardiac function and prospectively included in the DREPACOEUR registry. They underwent a 24-hour electrocardiogram monitoring (24h-Holter), transthoracic echocardiography, and laboratory tests on the same day. The primary end point was the occurrence of VA, defined as sustained or nonsustained ventricular tachycardia (VT), >500 premature ventricular contractions (PVCs) on 24h-Holter, or a recent history of VT ablation. The mean patient age was 46 ± 13 years, and 48% of the patients were male. Overall, VA was observed in 22 (22%) patients. Male sex (81% vs 34%; P = .02), impaired global longitudinal strain (GLS): -16% ± 1.9% vs -18.3% ± 2.7%; P = .02), and decreased platelet count (226 ± 96 giga per liter [G/L] vs 316 ± 130 G/L) were independently associated with VA. GLS correlated with PVC load every 24 hours (r = 0.39; P < .001) and a cutoff of -17.5% could predict VA with a sensitivity of 82% and a specificity of 63%. VAs are common in patients with SCA, especially in men. This pilot study uncovered GLS as a valuable parameter for improving rhythmic risk stratification.
Collapse
MESH Headings
- Adult
- Humans
- Male
- Middle Aged
- Female
- Pilot Projects
- Arrhythmias, Cardiac/etiology
- Death, Sudden, Cardiac/epidemiology
- Death, Sudden, Cardiac/etiology
- Death, Sudden, Cardiac/prevention & control
- Tachycardia, Ventricular/diagnosis
- Tachycardia, Ventricular/etiology
- Anemia, Sickle Cell/complications
Collapse
Affiliation(s)
- Thomas d'Humières
- Department of Physiology, FHU SENEC, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, INSERM IMRB U955, Université Paris Est, Créteil, France
- Sickle Cell Referral Center - UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, Université Paris Est, FHU SENEC, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - Joseph Saba
- Department of Physiology, FHU SENEC, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, INSERM IMRB U955, Université Paris Est, Créteil, France
| | - Laurent Savale
- Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 Pulmonary Hypertension, Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Marie Dupuy
- Department of Physiology, FHU SENEC, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, INSERM IMRB U955, Université Paris Est, Créteil, France
| | - Laurent Boyer
- Department of Physiology, FHU SENEC, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, INSERM IMRB U955, Université Paris Est, Créteil, France
| | - Henri Guillet
- Sickle Cell Referral Center - UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, Université Paris Est, FHU SENEC, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
- Department of Internal Medicine, Henri-Mondor University Hospital-UPEC, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Lara Alassaad
- Department of Physiology, FHU SENEC, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, INSERM IMRB U955, Université Paris Est, Créteil, France
| | - Gonzalo de Luna
- Sickle Cell Referral Center - UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, Université Paris Est, FHU SENEC, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
- Department of Internal Medicine, Henri-Mondor University Hospital-UPEC, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Sihem Iles
- Department of Physiology, FHU SENEC, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, INSERM IMRB U955, Université Paris Est, Créteil, France
| | - Anne L Pham Hung d'Alexandry d'Orengiani
- Sickle Cell Referral Center - UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, Université Paris Est, FHU SENEC, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - Yosr Zaouali
- Sickle Cell Referral Center - UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, Université Paris Est, FHU SENEC, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - Nouhaila Boukour
- Sickle Cell Referral Center - UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, Université Paris Est, FHU SENEC, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - Yanis Pelinski
- Sickle Cell Referral Center - UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, Université Paris Est, FHU SENEC, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - Laurent Messonnier
- Inter-university Laboratory of Human Movement Sciences EA 7424, Université Savoie Mont Blanc, Chambéry, France
| | - Etienne Audureau
- Department of Biostatistics, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, CEpiA IMRB U955, FHU SENEC, Université Paris Est, Créteil, France
| | - Haytham Derbel
- Department of Radiology, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Est, Créteil, France
| | - Anoosha Habibi
- Sickle Cell Referral Center - UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, Université Paris Est, FHU SENEC, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
- Department of Internal Medicine, Henri-Mondor University Hospital-UPEC, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Nicolas Lellouche
- Department of Cardiology, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Est, Créteil, France
| | - Geneviève Derumeaux
- Department of Physiology, FHU SENEC, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, INSERM IMRB U955, Université Paris Est, Créteil, France
| | - Pablo Bartolucci
- Sickle Cell Referral Center - UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, Université Paris Est, FHU SENEC, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
- Department of Internal Medicine, Henri-Mondor University Hospital-UPEC, Assistance Publique-Hôpitaux de Paris, Créteil, France
| |
Collapse
|
14
|
Mañú Pereira MDM, Colombatti R, Alvarez F, Bartolucci P, Bento C, Brunetta AL, Cela E, Christou S, Collado A, de Montalembert M, Dedeken L, Fenaux P, Galacteros F, Glenthøj A, Gutiérrez Valle V, Kattamis A, Kunz J, Lobitz S, McMahon C, Pellegrini M, Reidel S, Russo G, Santos Freire M, van Beers E, Kountouris P, Gulbis B. Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective. Lancet Haematol 2023:S2352-3026(23)00182-5. [PMID: 37451300 DOI: 10.1016/s2352-3026(23)00182-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 06/16/2023] [Accepted: 06/19/2023] [Indexed: 07/18/2023]
Abstract
Sickle cell disease is a hereditary multiorgan disease that is considered rare in the EU. In 2017, the Rare Diseases Plan was implemented within the EU and 24 European Reference Networks (ERNs) were created, including the ERN on Rare Haematological Diseases (ERN-EuroBloodNet), dedicated to rare haematological diseases. This EU initiative has made it possible to accentuate existing collaborations and create new ones. The project also made it possible to list all the needs of people with rare haematological diseases not yet covered health-care providers in the EU to allow optimised care of individuals with rare pathologies, including sickle cell disease. This Viewpoint is the result of joint work within 12 EU member states (ie, Belgium, Cyprus, Denmark, France, Germany, Greece, Ireland, Italy, Portugal, Spain, Sweden, and The Netherlands), all members of the ERN-EuroBloodNet. We describe the role of the ERN-EuroBloodNet to improve the overall approach to and the management of individuals with sickle cell disease in the EU through specific on the pooling of expertise, knowledge, and best practices; the development of training and education programmes; the strategy for systematic gathering and standardisation of clinical data; and its reuse in clinical research. Epidemiology and research strategies from ongoing implementation of the Rare Anaemia Disorders European Epidemiological Platform is depicted.
Collapse
Affiliation(s)
- María Del Mar Mañú Pereira
- Rare Anemia Disorders Research Laboratory, Cancer and Blood Disorders in Children, Vall d'Hebrón Institut de Recerca, Barcelona, Spain; Pediatric Hematology and Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
| | - Raffaella Colombatti
- Pediatric Hematology Oncology Unit, Department of Women's and Child's Health, Azienda Ospedale-Università degli Studi di Padova, Padua, Italy
| | - Federico Alvarez
- Information Processing and Telecommunications Center, Universidad Politécnica de Madrid, Madrid, Spain
| | - Pablo Bartolucci
- Sickle Cell and Red Cell Disorders Referral Center-UMGGR, Hôpitaux Universitaires Henri Mondor, Assistance Publique Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France; Institut Mondor de Recherche Biomédicale, Laboratory of Excellence LABEX GRex, Créteil, France
| | - Celeste Bento
- Hematology Department, University Hospital, Research Centre for Anthropology and Health (CIAS), University Coimbra, Coimbra, Portugal
| | - Angelo Loris Brunetta
- Thalassaemia International Federation, Nicosia, Cyprus; ERN-EuroBloodNet, Paris, France
| | - Elena Cela
- Pediatric Hematology and Oncology Unit, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain
| | | | - Anna Collado
- Rare Anemia Disorders Research Laboratory, Cancer and Blood Disorders in Children, Vall d'Hebrón Institut de Recerca, Barcelona, Spain; Pediatric Hematology and Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Mariane de Montalembert
- Department of General Pediatrics and Pediatric Infectious Disease, Sickle Cell Center, Necker-Enfants malades Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Laurence Dedeken
- Haemato-oncology, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium
| | - Pierre Fenaux
- Département d'hématologie et immunologie, hôpital St Louis, Assistance Publique Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
| | - Frédéric Galacteros
- Red Cell Genetic Disease Unit, Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, GHU Henri Mondor; U-PEC, Paris, France
| | - Andreas Glenthøj
- Department of Hematology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark
| | - Victoria Gutiérrez Valle
- Rare Anemia Disorders Research Laboratory, Cancer and Blood Disorders in Children, Vall d'Hebrón Institut de Recerca, Barcelona, Spain; Pediatric Hematology and Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Antonis Kattamis
- Thalassemia Unit, First Department of Pediatrics, National and Kapodistrian University of Athens-'Aghia Sophia' Children's Hospital, Athens, Greece
| | - Joachim Kunz
- Department of Pediatric Oncology, Hematology, Oncology and Immunology, University of Heidelberg, Heidelberg, Germany
| | - Stephan Lobitz
- Department of Pediatric Hematology and Oncology, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany
| | - Corrina McMahon
- Department of Haematology, Children's Health Ireland at Crumlin, University College Dublin, Ireland
| | - Mariangela Pellegrini
- Département d'hématologie et immunologie, hôpital St Louis, Assistance Publique Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
| | - Sara Reidel
- Rare Anemia Disorders Research Laboratory, Cancer and Blood Disorders in Children, Vall d'Hebrón Institut de Recerca, Barcelona, Spain; Pediatric Hematology and Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Giovanna Russo
- Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
| | - Miriam Santos Freire
- ERN-EuroBloodNet, Paris, France; Associação Portuguesa de Pais e Doentes com Hemoglobinopatias-APPDH, Almada, Portugal; European Hematology Association, The Hague, Netherlands; Portugal for the European Sickle Cell Federation, Brussels, Belgium
| | - Eduard van Beers
- Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Petros Kountouris
- Molecular Genetics Thalassaemia Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
| | - Béatrice Gulbis
- Laboratoire Hospitalier Universitaire de Bruxelles, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
15
|
Melica G, Bartolucci P, Audureau E, Le Corvoisier P, Habibi A, Gellen J, Selmane D, Michel M, Lacabaratz C, Levy Y. Immunological Efficacy of Pneumococcal Vaccination Including the 13-Valent Pneumococcal Conjugate Vaccine in Adult Patients With Sickle Cell Disease: Results of the Randomized DREVAC Controlled Trial. Clin Infect Dis 2023; 76:1949-1958. [PMID: 36705266 DOI: 10.1093/cid/ciad037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 01/05/2023] [Accepted: 01/20/2023] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND Patients with sickle cell disease (SCD) are at high risk for invasive pneumococcal diseases. The immunological efficacy of 13-valent conjugate pneumococcal vaccine (PCV13) followed by a 23-valent polysaccharide vaccine (PPSV23) is poorly documented in adults with SCD. METHODS This was a randomized open-labeled phase 2 study of the immunogenicity of PCV13 at week 0, followed by PPSV23 at week 4, compared with PPSV23 alone at week 4 in adult patients with SCD. The proportion of responders (4-fold increase in serotype-specific immunoglobulin [Ig] G antibodies) to ≥10 shared serotypes was assessed at week 8. Secondary end points were (1) geometric mean titers, (2) responders to 0-1, 2-5, 6-9, or 10-12 serotypes, (3) pneumococcal opsonophagocytic activity, and (4) response durability at weeks 24 and 96. RESULTS In total, 128 patients were randomized in the PCV13/PPSV23 (n = 63) or PPSV23-alone groups (n = 65). At week 8, 24.56% and 8.20% of patients from the PCV13/PPSV23 and PPSV23 groups, respectively, reached the primary end point (P = .02). These numbers were 36.2% and 8.7% for opsonophagocytic activity responders (P = .002). A combined PCV13/PPSV23 strategy improved the breadth of responses to 0-1, 2-5, 6-9, or 10-12 serotypes with 15.8%, 35%, 24.6%, and 24.6% versus 52.5%, 31%, 8%, and 8% in the PPSV23 group. At week 96, geometric mean titers were significantly higher in the PCV13/PPSV23 than in the PPSV23-alone group for 5 serotypes (4, 14, 19A, 19F, 23F). CONCLUSIONS A PCV13/PPSV23 regimen improved the breadth and magnitude of antibody responses against a large range of pneumococcal serotypes in adults with SCD. The sustainability of the immune response requires recall strategies.Clinical Trial Registration: NCT02274415.
Collapse
Affiliation(s)
- Giovanna Melica
- Clinical Immunology and Infectious Diseases Unit, Henri Mondor Hospital, APHP, Creteil, France
- Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est, Creteil, France
| | - Pablo Bartolucci
- Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence, Creteil, France
| | - Etienne Audureau
- Public Health Department, Henri Mondor Hospital, APHP, Mondor Institut of Biomedical Research Inserm U955, University Paris Est Creteil, Creteil, France
| | - Philippe Le Corvoisier
- Clinical Investigation Center 1430, Inserm, Henri Mondor Hospital, APHP, Creteil, France
| | - Anoosha Habibi
- Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence, Creteil, France
| | - Justine Gellen
- Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence, Creteil, France
| | - Dalia Selmane
- Public Health Department, Henri Mondor Hospital, APHP, Mondor Institut of Biomedical Research Inserm U955, University Paris Est Creteil, Creteil, France
| | - Marc Michel
- Internal Medicine Unit, Henri Mondor Hospital, APHP, Creteil, France
| | - Christine Lacabaratz
- Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est, Creteil, France
| | - Yves Levy
- Clinical Immunology and Infectious Diseases Unit, Henri Mondor Hospital, APHP, Creteil, France
- Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est, Creteil, France
| |
Collapse
|
16
|
Gendreau S, Cecchini J, Perier F, Razazi K, Carteaux G, De Prost N, Bartolucci P, Habibi A, Mekontso Dessap A. Effect of high-flow oxygen therapy on regional oxygen saturation during vaso-occlusive pain crisis: An observational study. Br J Haematol 2023. [PMID: 37060277 DOI: 10.1111/bjh.18812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 03/08/2023] [Accepted: 04/04/2023] [Indexed: 04/16/2023]
Affiliation(s)
- Segolene Gendreau
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Médecine Intensive Réanimation, Créteil, France
- Université Paris Est Créteil, Faculté de Santé de Créteil, Institut Mondor de Recherche Biomédicale-Groupe de recherche clinique CARMAS, Créteil, France
| | - Jérôme Cecchini
- Université Paris Est Créteil, Faculté de Santé de Créteil, Institut Mondor de Recherche Biomédicale-Groupe de recherche clinique CARMAS, Créteil, France
- Hôpital Intecommunal de Créteil, Service de réanimation et surveillance continue adulte, Créteil, France
| | - François Perier
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Médecine Intensive Réanimation, Créteil, France
- Université Paris Est Créteil, Faculté de Santé de Créteil, Institut Mondor de Recherche Biomédicale-Groupe de recherche clinique CARMAS, Créteil, France
| | - Keyvan Razazi
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Médecine Intensive Réanimation, Créteil, France
- Université Paris Est Créteil, Faculté de Santé de Créteil, Institut Mondor de Recherche Biomédicale-Groupe de recherche clinique CARMAS, Créteil, France
| | - Guillaume Carteaux
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Médecine Intensive Réanimation, Créteil, France
- Université Paris Est Créteil, Faculté de Santé de Créteil, Institut Mondor de Recherche Biomédicale-Groupe de recherche clinique CARMAS, Créteil, France
| | - Nicolas De Prost
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Médecine Intensive Réanimation, Créteil, France
- Université Paris Est Créteil, Faculté de Santé de Créteil, Institut Mondor de Recherche Biomédicale-Groupe de recherche clinique CARMAS, Créteil, France
| | - Pablo Bartolucci
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Unité des Maladies Génétiques du Globule Rouge, Créteil, France
| | - Anoosha Habibi
- Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Unité des Maladies Génétiques du Globule Rouge, Créteil, France
| | - Armand Mekontso Dessap
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Service de Médecine Intensive Réanimation, Créteil, France
- Université Paris Est Créteil, Faculté de Santé de Créteil, Institut Mondor de Recherche Biomédicale-Groupe de recherche clinique CARMAS, Créteil, France
| |
Collapse
|
17
|
Redjoul R, Beckerich F, de Luna G, Leclerc M, Hebert N, Sloma I, Menouche D, Bartolucci P, Maury S. ABO blood barrier to engraftment after allogeneic stem cell transplantation in sickle cell disease: A case-story with two successive HLA-matched sibling donors. Am J Hematol 2023; 98:692-696. [PMID: 36510370 DOI: 10.1002/ajh.26808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 11/30/2022] [Accepted: 12/06/2022] [Indexed: 12/15/2022]
Affiliation(s)
- Rabah Redjoul
- Hematology Department, AP-HP, Hôpital Henri Mondor, Créteil, France
| | | | - Gonzalo de Luna
- AP-HP, Hôpital Henri Mondor, Unité des maladies génétiques du globule rouge and Etablissement Français du Sang, Créteil, France
| | - Mathieu Leclerc
- Hematology Department, AP-HP, Hôpital Henri Mondor, Créteil, France
- IMRB, INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| | - Nicolas Hebert
- AP-HP, Hôpital Henri Mondor, Unité des maladies génétiques du globule rouge and Etablissement Français du Sang, Créteil, France
| | - Ivan Sloma
- IMRB, INSERM U955, Paris Est Créteil University UPEC, Créteil, France
- Laboratoire d'onco-hématologie Moléculaire, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Dehbia Menouche
- Hematology Department, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Pablo Bartolucci
- AP-HP, Hôpital Henri Mondor, Unité des maladies génétiques du globule rouge and Etablissement Français du Sang, Créteil, France
- IMRB, INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| | - Sébastien Maury
- Hematology Department, AP-HP, Hôpital Henri Mondor, Créteil, France
- IMRB, INSERM U955, Paris Est Créteil University UPEC, Créteil, France
| |
Collapse
|
18
|
Baron C, Cherkaoui S, Therrien-Laperriere S, Ilboudo Y, Poujol R, Mehanna P, Garrett ME, Telen MJ, Ashley-Koch AE, Bartolucci P, Rioux JD, Lettre G, Des Rosiers C, Ruiz M, Hussin JG. Gene-metabolite annotation with shortest reactional distance enhances metabolite genome-wide association studies results. bioRxiv 2023:2023.03.22.533869. [PMID: 36993181 PMCID: PMC10055409 DOI: 10.1101/2023.03.22.533869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/19/2023]
Abstract
Studies combining metabolomics and genetics, known as metabolite genome-wide association studies (mGWAS), have provided valuable insights into our understanding of the genetic control of metabolite levels. However, the biological interpretation of these associations remains challenging due to a lack of existing tools to annotate mGWAS gene-metabolite pairs beyond the use of conservative statistical significance threshold. Here, we computed the shortest reactional distance (SRD) based on the curated knowledge of the KEGG database to explore its utility in enhancing the biological interpretation of results from three independent mGWAS, including a case study on sickle cell disease patients. Results show that, in reported mGWAS pairs, there is an excess of small SRD values and that SRD values and p-values significantly correlate, even beyond the standard conservative thresholds. The added-value of SRD annotation is shown for identification of potential false negative hits, exemplified by the finding of gene-metabolite associations with SRD ≤1 that did not reach standard genome-wide significance cut-off. The wider use of this statistic as an mGWAS annotation would prevent the exclusion of biologically relevant associations and can also identify errors or gaps in current metabolic pathway databases. Our findings highlight the SRD metric as an objective, quantitative and easy-to-compute annotation for gene-metabolite pairs that can be used to integrate statistical evidence to biological networks.
Collapse
Affiliation(s)
- Cantin Baron
- Département de Biochimie et de Médecine Moléculaire, Université de Montréal, Québec, Canada
- Montreal Heart Institute, Québec, Canada
| | - Sarah Cherkaoui
- Montreal Heart Institute, Québec, Canada
- Division of Oncology and Children’s Research Center, University Children’s Hospital Zurich, University of Zurich, Switzerland
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France
| | | | - Yann Ilboudo
- Département de Biochimie et de Médecine Moléculaire, Université de Montréal, Québec, Canada
- Montreal Heart Institute, Québec, Canada
| | | | | | - Melanie E. Garrett
- Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, USA
| | - Marilyn J. Telen
- Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
| | | | - Pablo Bartolucci
- Université Paris Est Créteil, Hôpitaux Universitaires Henri Mondor, APHP, Sickle cell referral center – UMGGR, Créteil, France
- Université Paris Est Créteil, IMRB, Laboratory of excellence LABEX, Créteil, France
| | - John D. Rioux
- Département de Biochimie et de Médecine Moléculaire, Université de Montréal, Québec, Canada
- Montreal Heart Institute, Québec, Canada
- Département de Médecine, Université de Montréal, Québec, Canada
| | - Guillaume Lettre
- Montreal Heart Institute, Québec, Canada
- Département de Médecine, Université de Montréal, Québec, Canada
| | - Christine Des Rosiers
- Département de Biochimie et de Médecine Moléculaire, Université de Montréal, Québec, Canada
- Montreal Heart Institute, Québec, Canada
- Département de Nutrition, Université de Montréal, Québec, Canada
| | - Matthieu Ruiz
- Montreal Heart Institute, Québec, Canada
- Département de Nutrition, Université de Montréal, Québec, Canada
| | - Julie G. Hussin
- Montreal Heart Institute, Québec, Canada
- Département de Médecine, Université de Montréal, Québec, Canada
| |
Collapse
|
19
|
Pincez T, Lo KS, D'Orengiani ALPHD, Garrett ME, Brugnara C, Ashley-Koch AE, Telen MJ, Galacteros F, Joly P, Bartolucci P, Lettre G. Variation and impact of polygenic hematologic traits in monogenic sickle cell disease. Haematologica 2023; 108:870-881. [PMID: 36226494 PMCID: PMC9973495 DOI: 10.3324/haematol.2022.281180] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Indexed: 11/09/2022] Open
Abstract
Several of the complications observed in sickle cell disease (SCD) are influenced by variation in hematologic traits (HT), such as fetal hemoglobin (HbF) level and neutrophil count. Previous large-scale genome-wide association studies carried out in largely healthy individuals have identified thousands of variants associated with HT, which have then been used to develop multi-ancestry polygenic trait scores (PTS). Here, we tested whether these PTS associate with HT in SCD patients and if they can improve statistical models associated with SCD-related complications. In 2,056 SCD patients, we found that the PTS predicted less HT variance than in non-SCD individuals of African ancestry. This was particularly striking at the Duffy/DARC locus, where we observed an epistatic interaction between the SCD genotype and the Duffy null variant (rs2814778) that led to a two-fold weaker effect on neutrophil count. PTS for these HT which are measured as part of routine practice were not associated with complications in SCD. In contrast, we found that a simple PTS for HbF that includes only six variants explained a large fraction of the phenotypic variation (20.5-27.1%), associated with acute chest syndrome and stroke risk, and improved the statistical modeling of the vaso-occlusive crisis rate. Using Mendelian randomization, we found that increasing HbF by 4.8% reduces stroke risk by 39% (P=0.0006). Taken together, our results highlight the importance of validating PTS in large diseased populations before proposing their implementation in the context of precision medicine initiatives.
Collapse
Affiliation(s)
- Thomas Pincez
- Montreal Heart Institute, Montreal, Quebec, Canada; Department of Pediatrics, Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Universite de Montreal, Montreal, Quebec
| | - Ken Sin Lo
- Montreal Heart Institute, Montreal, Quebec
| | | | - Melanie E Garrett
- Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC
| | - Carlo Brugnara
- Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA
| | | | - Marilyn J Telen
- Department of Medicine, Division of Hematology, Duke University Medical Center, Durham, NC
| | - Frederic Galacteros
- Red Cell Genetic Disease Unit, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris Est, IMRB - U955 - Equipe no 2, Creteil
| | - Philippe Joly
- Unite Fonctionnelle 34445 'Biochimie des Pathologies Erythrocytaires', Laboratoire de Biochimie et Biologie Moleculaire Grand-Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France; Laboratoire Inter-Universitaire de Biologie de la Motricite (LIBM) EA7424, Equipe 'Biologie Vasculaire et du Globule Rouge', Universite Claude Bernard Lyon 1, Comite d'Universites et d'Etablissements (COMUE), Lyon
| | - Pablo Bartolucci
- Red Cell Genetic Disease Unit, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris Est, IMRB - U955 - Equipe no 2, Creteil
| | - Guillaume Lettre
- Montreal Heart Institute, Montreal, Quebec, Canada; Department of Medicine, Faculty of Medicine, Universite de Montreal, Montreal, Quebec.
| |
Collapse
|
20
|
Habibi A, Cannas G, Bartolucci P, Voskaridou E, Joseph L, Bernit E, Gellen-Dautremer J, Charneau C, Ngo S, Galactéros F. Outcomes of Pregnancy in Sickle Cell Disease Patients: Results from the Prospective ESCORT-HU Cohort Study. Biomedicines 2023; 11:biomedicines11020597. [PMID: 36831132 PMCID: PMC9953329 DOI: 10.3390/biomedicines11020597] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 02/09/2023] [Accepted: 02/11/2023] [Indexed: 02/19/2023] Open
Abstract
Sickle cell disease (SCD) refers to a group of inherited hemoglobin disorders in which sickle red blood cells display altered deformability, leading to a significant burden of acute and chronic complications, such as vaso-occlusive pain crises (VOCs). Hydroxyurea is a major therapeutic agent in adult and pediatric sickle cell patients. This treatment is an alternative to transfusion in some complications. Indeed, it increases hemoglobin F and has an action on the endothelial adhesion of red blood cells, leukocytes, and platelets. Although the safety profile of hydroxyurea (HU) in patients with sickle cell disease has been well established, the existing literature on HU exposure during pregnancy is limited and incomplete. Pregnancy in women with SCD has been identified as a high risk for the mother and fetus due to the increased incidence of maternal and non-fetal complications in various studies and reports. For women on hydroxyurea at the time of pregnancy, transfusion therapy should probably be initiated after pregnancy. In addition, there is still a significant lack of knowledge about the incidence of pregnancy, fetal and maternal outcomes, and management of pregnant women with SCD, making it difficult to advise women or clinicians on outcomes and best practices. Therefore, the objective of this study was to describe pregnancy outcomes (n = 128) reported in the noninterventional European Sickle Cell Disease COhoRT-HydroxyUrea (ES-CORT-HU) study. We believe that our results are important and relevant enough to be shared with the scientific community.
Collapse
Affiliation(s)
- Anoosha Habibi
- Sickle Cell Referral Center, Internal Medicine Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, U-PEC, 94000 Créteil, France
- INSERM-U955, Institut Mondor, Université Paris-Est Créteil, Team 2 Transfusion et Maladies du Globule Rouge, Laboratoire d’Excellence GR-Ex, 94000 Créteil, France
- Correspondence:
| | | | - Pablo Bartolucci
- Sickle Cell Referral Center, Internal Medicine Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, U-PEC, 94000 Créteil, France
- INSERM-U955, Institut Mondor, Université Paris-Est Créteil, Team 2 Transfusion et Maladies du Globule Rouge, Laboratoire d’Excellence GR-Ex, 94000 Créteil, France
| | - Ersi Voskaridou
- Thalassemia and Sickle Cell Disease Center, “Laiko” General Hospital, 115 27 Athens, Greece
| | - Laure Joseph
- Biotherapy Department, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris, 75610 Paris, France
| | - Emmanuelle Bernit
- Sickle Cell Referral Center, CHU Guadeloupe-Pôle Parents-Enfants—Hôpital Ricou, BP465, Pointe à Pitre, CEDEX, 97159 Guadeloupe, France
| | | | | | | | - Frédéric Galactéros
- Sickle Cell Referral Center, Internal Medicine Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, U-PEC, 94000 Créteil, France
- INSERM-U955, Institut Mondor, Université Paris-Est Créteil, Team 2 Transfusion et Maladies du Globule Rouge, Laboratoire d’Excellence GR-Ex, 94000 Créteil, France
| |
Collapse
|
21
|
Martino S, Turki RC, Zouiti F, Fort R, Pakdaman S, Forté S, Menouche D, Calvet D, Rupp T, Pirenne F, Bartolucci P. Near-Infrared Spectroscopy Demonstrates the Benefit of Erythracytapheresis in Sickle Cell Disease Adult Patients with Cerebral Vasculopathy. J Clin Med 2023; 12:jcm12041256. [PMID: 36835792 PMCID: PMC9966188 DOI: 10.3390/jcm12041256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 01/26/2023] [Accepted: 02/03/2023] [Indexed: 02/09/2023] Open
Abstract
BACKGROUND Cerebral vasculopathy can induce chronic cerebral hypoperfusion leading to stroke in patients with sickle cell disease (SCD) and is treated by blood exchange transfusion (BET). However, no prospective clinical study has demonstrated the benefit of BET in adults with SCD and cerebral vasculopathy. Near Infrared Spectroscopy (NIRS) is a recent non-invasive method complementary to Magnetic Resonance Imaging (MRI). We evaluated cerebral perfusion using NIRS during erythracytapheresis in patients with SCD with and without steno-occlusive arterial disease. METHODS We conducted a monocentric, prospective study in 16 adults with SCD undergoing erythracytapheresis in 2014. Among them, 10 had cerebral steno-occlusive arterial disease. NIRS measured the relative amounts of oxyhemoglobin (OxyHb), deoxyhemoglobin (DeoxyHb) and total hemoglobin (Total Hb) in brain tissue and in muscle. RESULTS In cerebral hemispheres associated with steno-occlusive arterial disease, we observed a significant increase of OxyHb and Total Hb during BET, without modification of DeoxyHb. CONCLUSION Using NIRS during BET showed that BET improves cerebral perfusion in adult patients with SCD with cerebral vasculopathy.
Collapse
Affiliation(s)
- Suella Martino
- Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Creteil, France
| | - Rym Chouk Turki
- Etablissement Français du Sang, Île-de-France Mondor, 94000 Creteil, France
| | - Fouzia Zouiti
- Etablissement Français du Sang, Île-de-France Mondor, 94000 Creteil, France
| | - Romain Fort
- Department of Internal Medicine, Edouard Herriot University Hospital, 69003 Lyon, France
| | - Sadaf Pakdaman
- Etablissement Français du Sang, Île-de-France Mondor, 94000 Creteil, France
| | - Stéphanie Forté
- Division of Hematology and Oncology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC H2X 3E4, Canada
| | - Dehbia Menouche
- Department of Apheresis, Henri Mondor University Hospital, UPEC, APHP, 94000 Creteil, France
| | - David Calvet
- Department of Neurology, Sainte-Anne Hospital, 75014 Paris, France
| | - Thomas Rupp
- Interuniversity Laboratory of Human Movement Biology, University Savoie Mont Blanc, 73000 Chambery, France
| | - France Pirenne
- Etablissement Français du Sang, Île-de-France Mondor, 94000 Creteil, France
- Laboratoire D’Excellence, GRex, Institut Mondor, INSERM U955 Equipe 2, 94000 Creteil, France
| | - Pablo Bartolucci
- Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Creteil, France
- Laboratoire D’Excellence, GRex, Institut Mondor, INSERM U955 Equipe 2, 94000 Creteil, France
- Correspondence:
| |
Collapse
|
22
|
Flevari P, Voskaridou E, Galactéros F, Cannas G, Loko G, Joseph L, Bartolucci P, Gellen-Dautremer J, Bernit E, Charneau C, Habibi A. Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review. Biomedicines 2022; 10:biomedicines10123201. [PMID: 36551957 PMCID: PMC9775156 DOI: 10.3390/biomedicines10123201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 12/01/2022] [Accepted: 12/08/2022] [Indexed: 12/14/2022] Open
Abstract
The safety profile of hydroxyurea (HU) in patients with sickle-cell disease (SCD) is relatively well known. However, despite the suspected association of HU with myeloid neoplasms in myeloproliferative neoplasms (MPN), and the publication of sporadic reports of myeloid malignancies in SCD patients treated with HU, the possible excess risk imparted by HU in this population having an increasing life expectancy has failed to be demonstrated. Herein, we report one case of myelodysplastic syndrome emanating from the results on safety and effectiveness of HU on the largest European cohort of 1903 HU-treated adults and children who were followed-up prospectively in an observational setting over 10 years, accounting for a total exposure of 7309.5 patient-years. A comparison of this single case with previously published similar cases did not allow us to draw any significant conclusions due to the paucity of these events.
Collapse
Affiliation(s)
- Pagona Flevari
- Centre of Excellence in Rare Hematological Disease-Hemoglobinopathies, Laiko General Hospital, 11527 Athens, Greece
- Correspondence: (P.F.); (E.V.)
| | - Ersi Voskaridou
- Centre of Excellence in Rare Hematological Disease-Hemoglobinopathies, Laiko General Hospital, 11527 Athens, Greece
- Correspondence: (P.F.); (E.V.)
| | - Frédéric Galactéros
- Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, APHP, U-PEC, 94000 Créteil, France
| | - Giovanna Cannas
- Hospices Civils de Lyon, Edouard-Herriot Hospital, Internal Medicine, Reference Centre for Sickle-Cell Disease, Thalassemia and Other Red Blood Cell Disorders, 69003 Lyon, France
| | - Gylna Loko
- Martinique Hospital, 97212 Martinique, France
| | - Laure Joseph
- Biotherapy Department, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris, 75610 Paris, France
| | - Pablo Bartolucci
- Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, APHP, U-PEC, 94000 Créteil, France
| | - Justine Gellen-Dautremer
- Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, APHP, U-PEC, 94000 Créteil, France
| | - Emmanuelle Bernit
- Antilles-Guyane Reference Centre for Sickle-Cell Disease, Thalassemia and Other Red Blood Cell Disorders, Pointe à Pitre, 97157 Guadeloupe, France
| | - Corine Charneau
- Antilles-Guyane Reference Centre for Sickle-Cell Disease, Thalassemia and Other Red Blood Cell Disorders, Pointe à Pitre, 97157 Guadeloupe, France
| | - Anoosha Habibi
- Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, APHP, U-PEC, 94000 Créteil, France
| |
Collapse
|
23
|
Azoyan L, Lombardi Y, Rech J, Haymann J, Wu C, Le Jeune S, Affo L, Chantalat Auger C, Bartolucci P, Leblanc J, Steichen O. Risque d’insuffisance rénale aiguë après injection de produit de contraste iodé chez les adultes atteints de drépanocytose : une série de cas autocontrôlés issue d’un entrepôt de données de santé multicentrique. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
24
|
Alkobtawi M, Sbeih M, Souaid K, Ngô QT, Nassar D, Arbes H, Guillet H, Habibi A, Bartolucci P, Castela M, Aractingi S, Oulès B. Contribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcers. Haematologica 2022. [DOI: 10.3324/haematol.2022.281140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Indexed: 11/11/2022] Open
Abstract
Leg ulcers are a major complication of sickle cell disease (SCD) that can cause severe complications. They are particularly challenging to treat and therapeutic innovation is needed. We previously showed that SCD ulcers display a delayed wound healing due to decreased angiogenesis. During pregnancy, fetal microchimeric cells (FMC) transferred to the mothers are recruited to maternal wounds and improve angiogenesis. After delivery, FMC persist in maternal bone marrow for decades. Here, we questioned whether fetal cells could also improve SCD ulcers in the post-partum setting. We found that skin healing was similarly improved in post-partum mice and in pregnant mice, through increased proliferation and angiogenesis. In a SCD mouse model that recapitulates SCD refractory ulcers, we showed that post-partum SCD mice healed more quickly as compared to virgin ones. This was associated with the recruitment of fetal cells in maternal wounds where they harbored markers of leukocytes and endothelial cells. In a retrospective cohort of SCD patients, we demonstrated using several parameters that ever parous SCD women had a decreased burden related to leg ulcers compared to nulliparous women. Taken together, these results indicate that healing capacities of FMC are maintained long after delivery and may be targeted to promote wound healing in post-partum SCD patients.
Collapse
|
25
|
Grunenwald A, Peliconi J, Revel M, Lavergne J, Voilin E, Bartolucci P, Frémeaux-Bacchi V, Roumenina L. Implication de l’activation du complément dans les lésions d’organes notamment rénales de la drépanocytose chez des patients et dans un modèle murin. Nephrol Ther 2022. [DOI: 10.1016/j.nephro.2022.07.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
26
|
De Luna G, Habibi A, Odièvre M, Guillet H, Guiraud V, Cougoul P, Carpentier B, Loko G, Guichard I, Ourghanlian C, Pawlotsky JM, Mahevas M, Limal N, Michel M, Mekontso‐Dessap A, Arlet J, Bartolucci P. Blood exchange transfusion with dexamethasone and Tocilizumab for management of hospitalized patients with sickle cell disease and severe COVID-19: Preliminary evaluation of a novel algorithm. Am J Hematol 2022; 97:E260-E264. [PMID: 35385170 PMCID: PMC9073971 DOI: 10.1002/ajh.26563] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 03/28/2022] [Accepted: 03/31/2022] [Indexed: 11/09/2022]
Affiliation(s)
- Gonzalo De Luna
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐ UPEC, AP‐HP Créteil France
| | - Anoosha Habibi
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐ UPEC, AP‐HP Créteil France
| | - Marie‐Hélène Odièvre
- Armand‐Trousseau Hospital, Service de Pédiatrie Center for Sickle Cell Disease Paris France
| | - Henri Guillet
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐ UPEC, AP‐HP Créteil France
| | - Vincent Guiraud
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐ UPEC, AP‐HP Créteil France
| | - Pierre Cougoul
- Institut Universitaire du Cancer Toulouse Oncopole Médecine Interne Toulouse France
| | - Benjamin Carpentier
- Department of Hematology Hôpital Saint‐Vincent de Paul, Hématologie Lille France
| | - Gylna Loko
- Sickle Cell Center University of the French West Indies, CHU de Martinique Fort de France France
| | | | | | - Jean Michel Pawlotsky
- CHU Henri Mondor, National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor Université Paris‐Est Creteil Île‐de‐France France
| | - Matthieu Mahevas
- CHU Henri Mondor Internal Medicine, Reference center of autoimmune cytopenias Créteil France
| | - Nicolas Limal
- CHU Henri Mondor Internal Medicine, Reference center of autoimmune cytopenias Créteil France
| | - Marc Michel
- CHU Henri Mondor Internal Medicine, Reference center of autoimmune cytopenias Créteil France
| | | | - Jean‐Benoît Arlet
- Sickle Cell Referral Center, France, Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Pablo Bartolucci
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐ UPEC, AP‐HP Créteil France
| |
Collapse
|
27
|
Kim-Anh NP, Kiger L, Decrouy X, Bencheikh L, Habibi A, Pirenne F, Roumenina L, Bartolucci P. S299: ROLE OF RED BLOOD CELL MEMBRANE-DERIVED PARTICLES ON ENDOTHELIAL DAMAGES DURING ONSET STAGE OF DELAYED HEMOLYTIC TRANSFUSION REACTION. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000844088.18349.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
28
|
Januel L, Merlet AN, He Z, Hourdé C, Bartolucci P, Gellen B, Galactéros F, Messonnier LA, Féasson L. Skeletal Muscle Satellite Cells in Sickle Cell Disease Patients and Their Responses to a Moderate-intensity Endurance Exercise Training Program. J Histochem Cytochem 2022; 70:415-426. [PMID: 35642249 DOI: 10.1369/00221554221103905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We previously demonstrated that 8 weeks of moderate-intensity endurance training is safe and improves muscle function and characteristics of sickle cell disease (SCD) patients. Here, we investigated skeletal muscle satellite cells (SCs) in SCD patients and their responses to a training program. Fifteen patients followed the training program while 18 control patients maintained a normal lifestyle. Biopsies of the vastus lateralis muscle were performed before and after training. After training, the cross-sectional area and myonuclear content in type I fibers were slightly increased in the training patients compared to non-training patients. The SC pool was unchanged in type I fibers while it was slightly decreased in type II fibers in the training patients compared to non-training patients. No necrotic fibers were detected in patients before or after training. Therefore, the slight myonuclear accretion in type I fibers in trained SCD patients may highlight the contribution of SCs to training-induced slight type I fiber hypertrophy without expansion of the SC pool. The low training intensity and the short duration of training sessions could explain the low SC response to the training program. However, the lack of necrotic fibers suggests that the training program seemed to be safe for patients' muscle tissue.
Collapse
Affiliation(s)
- Léa Januel
- Univ Lyon, UJM-Saint-Etienne, Laboratoire Interuniversitaire de Biologie de la Motricité, Saint-Priest en Jarez, France
| | - Angèle N Merlet
- Univ Lyon, UJM-Saint-Etienne, Laboratoire Interuniversitaire de Biologie de la Motricité, Saint-Etienne, France.,Unité de Myologie, Service de Physiologie Clinique et de l'Exercice, Hôpital Universitaire de Saint-Etienne, Saint-Etienne, France
| | - Zhiguo He
- Biologie, Ingénierie et Imagerie de la Greffe de Cornée, Université de Lyon and Université Jean Monnet, Saint-Etienne, France
| | - Christophe Hourdé
- Université Savoie Mont Blanc, Laboratoire Interuniversitaire de Biologie de la Motricité, Chambéry, France
| | - Pablo Bartolucci
- Service de Médecine Interne, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France.,Service de Santé Publique, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Barnabas Gellen
- Service de Réhabilitation Cardiaque, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Frédéric Galactéros
- Service de Médecine Interne, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France.,Service de Santé Publique, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Laurent A Messonnier
- Université Savoie Mont Blanc, Laboratoire Interuniversitaire de Biologie de la Motricité, Chambéry, France
| | - Léonard Féasson
- Univ Lyon, UJM-Saint-Etienne, Laboratoire Interuniversitaire de Biologie de la Motricité, Saint-Etienne, France.,Unité de Myologie, Service de Physiologie Clinique et de l'Exercice, Hôpital Universitaire de Saint-Etienne, Saint-Etienne, France
| |
Collapse
|
29
|
van der Veen S, van Dijk M, Jans J, Verhoeven-Duif N, van Wijk R, Bartels M, Mañú Pereira M, Colombatti R, Martella M, Munaretto V, Boaro M, Bartolucci P, Cnossen M, Biemond B, van Beers E. P1500: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE. Hemasphere 2022. [PMCID: PMC9429661 DOI: 10.1097/01.hs9.0000848856.08012.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
30
|
Mansour‐Hendili L, Flamarion E, Michel M, Morbieu C, Gameiro C, Sloma I, Badaoui B, Darnige L, Camard M, Lunati‐Rozie A, Aissat A, Tarfi S, Friedrich C, Picard V, Garçon L, Abermil N, Kaltenbach S, Radford‐Weiss I, Kosmider O, Fanen P, Bartolucci P, Godeau B, Galactéros F, Funalot B. Acquired spherocytosis due to somatic ANK1 mutations as a manifestation of clonal hematopoiesis in elderly patients. Am J Hematol 2022; 97:E285-E288. [PMID: 35560067 DOI: 10.1002/ajh.26593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 05/02/2022] [Accepted: 05/05/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Lamisse Mansour‐Hendili
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Créteil France
| | - Edouard Flamarion
- Service de Médecine Interne Hôpital Européen Georges Pompidou, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Marc Michel
- Service de Médecine Interne AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Caroline Morbieu
- Service de Médecine Interne AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Christine Gameiro
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Ivan Sloma
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
- Département d'Hématologie et d'Immunologie AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Bouchra Badaoui
- Département d'Hématologie et d'Immunologie AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Luc Darnige
- Département d'Hématologie Hôpital Européen Georges Pompidou, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Marion Camard
- Service de Médecine Interne Hôpital Européen Georges Pompidou, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Ariane Lunati‐Rozie
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Abdelrazak Aissat
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Sihem Tarfi
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
- Département d'Hématologie et d'Immunologie AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Chloé Friedrich
- Laboratoire d'Hématologie Hôpital Cochin, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Véronique Picard
- Département d'Hématologie Biologique Hôpital Bicêtre, AP‐HP, Université Paris Saclay Le Kremlin‐Bicêtre France
| | - Loïc Garçon
- Laboratoire Hématopoïèse et Immunologie (HEMATIM) EA4666 Université Picardie Jules Verne Amiens France
- Service d'Hématologie Biologique Centre Hospitalier Universitaire Amiens France
- Service de Génétique Constitutionnelle Centre Hospitalier Universitaire Amiens France
| | - Nasséra Abermil
- Centre de Recherche Saint‐Antoine Sorbonne Université, Inserm, Hôpital Saint‐Antoine Paris France
- Service d'Hématologie Biologique Hôpital Saint‐Antoine, AP‐HP, Sorbonne Université Paris France
| | - Sophie Kaltenbach
- Service de Cytogénétique Hôpital Necker enfants malades, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Isabelle Radford‐Weiss
- Service de Cytogénétique Hôpital Necker enfants malades, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Olivier Kosmider
- Laboratoire d'Hématologie Hôpital Cochin, AP‐HP, Centre‐Université Paris Cité Paris France
| | - Pascale Fanen
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Pablo Bartolucci
- Université Paris‐Est Créteil IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Créteil France
- Red Cell Disease Referral Center—UMGGR AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Bertrand Godeau
- Service de Médecine Interne AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| | - Frédéric Galactéros
- Université Paris‐Est Créteil IMRB Equipe Pirenne, Laboratoire d'excellence LABEX GRex Créteil France
- Red Cell Disease Referral Center—UMGGR AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
| | - Benoît Funalot
- Département de Biochimie‐Biologie Moléculaire, Pharmacologie, Génétique Médicale AP‐HP, Hôpitaux Universitaires Henri Mondor Créteil France
- Université Paris‐Est Créteil, INSERM, IMRB Créteil France
| |
Collapse
|
31
|
Bencheikh L, Nguyen KA, Chadebech P, Kiger L, Bodivit G, Jouard A, Pakdaman S, Adypagavane S, Audureau E, Tebbakha K, Bocquet T, Mignen B, Hebert N, Seguin M, Pirenne F, Sowemimo-Coker S, Dunham A, Bartolucci P. Preclinical evaluation of the preservation of red blood cell concentrates by hypoxic storage technology for transfusion in sickle cell disease. Haematologica 2022; 107:1944-1949. [PMID: 35354249 PMCID: PMC9335112 DOI: 10.3324/haematol.2021.279721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Indexed: 12/05/2022] Open
Affiliation(s)
- Laura Bencheikh
- Etablissement Français du Sang (EFS) Ile-de-France; Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil
| | - Kim-Anh Nguyen
- Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France; Institut Imagine, Paris
| | - Philippe Chadebech
- Etablissement Français du Sang (EFS) Ile-de-France; Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil
| | - Laurent Kiger
- Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil
| | - Gwellaouen Bodivit
- Etablissement Français du Sang (EFS) Ile-de-France; Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil
| | - Alicia Jouard
- Etablissement Français du Sang (EFS) Ile-de-France; Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil
| | | | - Sandia Adypagavane
- Etablissement Français du Sang (EFS) Ile-de-France; Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil
| | - Etienne Audureau
- CHU Henri Mondor, Assistance publique-hôpitaux de Paris, Creteil
| | | | | | | | - Nicolas Hebert
- Etablissement Français du Sang (EFS) Ile-de-France; Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil
| | - Marion Seguin
- Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil
| | - France Pirenne
- Etablissement Français du Sang (EFS) Ile-de-France; Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil
| | | | | | - Pablo Bartolucci
- Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France; CHU Henri Mondor, Assistance publique-hôpitaux de Paris, Creteil.
| |
Collapse
|
32
|
Arlet J, Lionnet F, Khimoud D, Joseph L, Montalembert M, Morisset S, Garou A, Cannas G, Cougoul P, Guitton C, Holvoet L, Odièvre M, Cheminet G, Bartolucci P, Santin A, Bernit E, Luna G. Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France. Am J Hematol 2022; 97:E86-E91. [PMID: 34882837 PMCID: PMC9011445 DOI: 10.1002/ajh.26432] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 12/05/2021] [Accepted: 12/06/2021] [Indexed: 01/28/2023]
Affiliation(s)
- Jean‐Benoît Arlet
- French Sickle Cell Referral Center France
- Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
| | - François Lionnet
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Internal Medicine Department, Tenon Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Djamal Khimoud
- French Sickle Cell Referral Center France
- Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
| | - Laure Joseph
- French Sickle Cell Referral Center France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Service de Biothérapie, Necker‐Enfants malades Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Mariane Montalembert
- French Sickle Cell Referral Center France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Department of General Pediatrics and Pediatric Infectious Diseases, Necker‐Enfants Malades Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | | | - Alain Garou
- French Sickle Cell Referral Center France
- Pediatric Department, Centre Hospitalier de Mayotte Rue de l'hôpital Mayotte France
| | - Giovanna Cannas
- French Sickle Cell Referral Center France
- Internal Medicine Department Hospices Civils Lyon France
| | - Pierre Cougoul
- French Sickle Cell Referral Center France
- Internal Medicine Department IUCT Oncopole, CHU de Toulouse France
| | - Corinne Guitton
- French Sickle Cell Referral Center France
- Pediatric Department, Bicetre Hospital, Bicêtre Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Laurent Holvoet
- French Sickle Cell Referral Center France
- Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
- Pediatric Department, Robert Debré Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Marie‐Hélène Odièvre
- French Sickle Cell Referral Center France
- Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
- Pediatric Department, Hôpital Armand Trousseau Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Geoffrey Cheminet
- French Sickle Cell Referral Center France
- Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
| | - Pablo Bartolucci
- French Sickle Cell Referral Center France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Department of Internal Medicine, Mondor Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Aline Santin
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Internal Medicine Department, Tenon Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Emmanuelle Bernit
- French Sickle Cell Referral Center France
- Unité Transversale de la Drépanocytose CHU de Guadeloupe Pointe à Pitre France
| | - Gonzalo Luna
- French Sickle Cell Referral Center France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Department of Internal Medicine, Mondor Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | | |
Collapse
|
33
|
Forté S, De Luna G, Abdulrehman J, Fadiga N, Pestrin O, Pham Hung d’Alexandry d’Orengiani AL, Aneke JC, Guillet H, Budhram D, Habibi A, Ward R, Bartolucci P, Kuo KHM. Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study. J Clin Med 2022; 11:jcm11051193. [PMID: 35268283 PMCID: PMC8910838 DOI: 10.3390/jcm11051193] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 02/14/2022] [Accepted: 02/18/2022] [Indexed: 12/16/2022] Open
Abstract
Sickle cell disease (SCD) induces a chronic prothrombotic state. Central venous access devices (CVADs) are commonly used for chronic transfusions and iron chelation in this population. CVADs are an additional venous thromboembolism (VTE) risk factor. The role of thromboprophylaxis in this setting is uncertain. The objectives are: (1) to determine whether thromboprophylaxis reduces VTE risk in SCD patients with CVAD and (2) to explore characteristics associated with VTE risk. We identified adults with SCD and CVAD intended for chronic use (≥3 months) at two comprehensive SCD centers. Thromboprophylaxis presence; type; intensity; and patient-, catheter-, and treatment-related VTE risk factors were recorded. Among 949 patients, 49 had a CVAD (25 without and 24 with VTE prophylaxis). Thromboprophylaxis type and intensity varied widely. Patients without thromboprophylaxis had higher VTE rates (rate ratio (RR) = 4.0 (95% confidence interval: 1.2−12.6), p = 0.02). Hydroxyurea was associated with lower VTE rates (RR = 20.5 (6.4−65.3), p < 0.001). PICC lines and Vortex and Xcela Power implantable devices were associated with higher rates compared with Port-a-Cath (RR = 5.8 (1.3−25.9), p = 0.02, and RR = 58.2 (15.0−225.0), p < 0.001, respectively). Thromboprophylaxis, hydroxyurea, and CVAD subtype were independently associated with VTE. The potentially protective role of thromboprophylaxis and hydroxyurea for VTE prevention in patients with SCD and CVAD merits further exploration.
Collapse
Affiliation(s)
- Stéphanie Forté
- Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada; (S.F.); (J.A.); (N.F.); (O.P.); (J.C.A.); (D.B.); (R.W.)
| | - Gonzalo De Luna
- Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Créteil, France; (G.D.L.); (A.-L.P.H.d.d.); (H.G.); (A.H.); (P.B.)
| | - Jameel Abdulrehman
- Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada; (S.F.); (J.A.); (N.F.); (O.P.); (J.C.A.); (D.B.); (R.W.)
| | - Nafanta Fadiga
- Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada; (S.F.); (J.A.); (N.F.); (O.P.); (J.C.A.); (D.B.); (R.W.)
| | - Olivia Pestrin
- Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada; (S.F.); (J.A.); (N.F.); (O.P.); (J.C.A.); (D.B.); (R.W.)
| | - Anne-Laure Pham Hung d’Alexandry d’Orengiani
- Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Créteil, France; (G.D.L.); (A.-L.P.H.d.d.); (H.G.); (A.H.); (P.B.)
| | - John Chinawaeze Aneke
- Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada; (S.F.); (J.A.); (N.F.); (O.P.); (J.C.A.); (D.B.); (R.W.)
| | - Henri Guillet
- Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Créteil, France; (G.D.L.); (A.-L.P.H.d.d.); (H.G.); (A.H.); (P.B.)
| | - Dalton Budhram
- Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada; (S.F.); (J.A.); (N.F.); (O.P.); (J.C.A.); (D.B.); (R.W.)
| | - Anoosha Habibi
- Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Créteil, France; (G.D.L.); (A.-L.P.H.d.d.); (H.G.); (A.H.); (P.B.)
| | - Richard Ward
- Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada; (S.F.); (J.A.); (N.F.); (O.P.); (J.C.A.); (D.B.); (R.W.)
| | - Pablo Bartolucci
- Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Créteil, France; (G.D.L.); (A.-L.P.H.d.d.); (H.G.); (A.H.); (P.B.)
- Laboratoire D’Excellence, GRex, Institut Mondor, INSERM U955 Equipe 2, 94000 Créteil, France
| | - Kevin H. M. Kuo
- Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada; (S.F.); (J.A.); (N.F.); (O.P.); (J.C.A.); (D.B.); (R.W.)
- Correspondence:
| |
Collapse
|
34
|
Magrin E, Semeraro M, Hebert N, Joseph L, Magnani A, Chalumeau A, Gabrion A, Roudaut C, Marouene J, Lefrere F, Diana JS, Denis A, Neven B, Funck-Brentano I, Negre O, Renolleau S, Brousse V, Kiger L, Touzot F, Poirot C, Bourget P, El Nemer W, Blanche S, Tréluyer JM, Asmal M, Walls C, Beuzard Y, Schmidt M, Hacein-Bey-Abina S, Asnafi V, Guichard I, Poirée M, Monpoux F, Touraine P, Brouzes C, de Montalembert M, Payen E, Six E, Ribeil JA, Miccio A, Bartolucci P, Leboulch P, Cavazzana M. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial. Nat Med 2022; 28:81-88. [PMID: 35075288 DOI: 10.1038/s41591-021-01650-w] [Citation(s) in RCA: 38] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 11/30/2021] [Indexed: 01/19/2023]
Abstract
Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are the most prevalent monogenic disorders worldwide. Trial HGB-205 ( NCT02151526 ) aimed at evaluating gene therapy by autologous CD34+ cells transduced ex vivo with lentiviral vector BB305 that encodes the anti-sickling βA-T87Q-globin expressed in the erythroid lineage. HGB-205 is a phase 1/2, open-label, single-arm, non-randomized interventional study of 2-year duration at a single center, followed by observation in long-term follow-up studies LTF-303 ( NCT02633943 ) and LTF-307 ( NCT04628585 ) for TDT and SCD, respectively. Inclusion and exclusion criteria were similar to those for allogeneic transplantation but restricted to patients lacking geno-identical, histocompatible donors. Four patients with TDT and three patients with SCD, ages 13-21 years, were treated after busulfan myeloablation 4.6-7.9 years ago, with a median follow-up of 4.5 years. Key primary endpoints included mortality, engraftment, replication-competent lentivirus and clonal dominance. No adverse events related to the drug product were observed. Clinical remission and remediation of biological hallmarks of the disease have been sustained in two of the three patients with SCD, and frequency of transfusions was reduced in the third. The patients with TDT are all transfusion free with improvement of dyserythropoiesis and iron overload.
Collapse
Affiliation(s)
- Elisa Magrin
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Michaela Semeraro
- Centre d'Investigation Clinique-Unité de Recherche Clinique, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Université de Paris, Paris, France
| | - Nicolas Hebert
- Univ Paris Est Creteil, INSERM, EFS, IMRB, Créteil, France.,Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Laure Joseph
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Alessandra Magnani
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Anne Chalumeau
- IMAGINE Institute, Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Aurélie Gabrion
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Cécile Roudaut
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Jouda Marouene
- Centre d'Investigation Clinique-Unité de Recherche Clinique, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Francois Lefrere
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Jean-Sebastien Diana
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Adeline Denis
- IMAGINE Institute, Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Bénédicte Neven
- Pediatric Immunology and Hematology Department, Hôpital Necker Enfants-Malades, Paris, France
| | - Isabelle Funck-Brentano
- Pediatric Immunology and Hematology Department, Hôpital Necker Enfants-Malades, Paris, France
| | - Olivier Negre
- CEA, INSERM, Université Paris-Saclay, Division of Innovative Therapies, Institut François Jacob, Fontenay aux Roses, France.,Bluebird Bio, Inc., Cambridge, MA, USA
| | - Sylvain Renolleau
- Pediatric Intensive Care Unit, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Valentine Brousse
- Department of General Pediatrics and Pediatric Infectious Diseases, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Laurent Kiger
- Univ Paris Est Creteil, INSERM, EFS, IMRB, Créteil, France
| | - Fabien Touzot
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Catherine Poirot
- Department of Hematology, Fertility Preservation, Hôpital Saint Louis, Paris, France.,Sorbonne Université, Paris, France
| | - Philippe Bourget
- Pharmacy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Wassim El Nemer
- Institut National de la Transfusion Sanguine (INTS), Paris, France
| | - Stéphane Blanche
- Pediatric Immunology and Hematology Department, Hôpital Necker Enfants-Malades, Paris, France
| | - Jean-Marc Tréluyer
- Centre d'Investigation Clinique-Unité de Recherche Clinique, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Université de Paris, Paris, France
| | | | | | - Yves Beuzard
- Univ Paris Est Creteil, INSERM, EFS, IMRB, Créteil, France.,CEA, INSERM, Université Paris-Saclay, Division of Innovative Therapies, Institut François Jacob, Fontenay aux Roses, France
| | | | - Salima Hacein-Bey-Abina
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Vahid Asnafi
- Université de Paris, Institut Necker-Enfants Malades, INSERM U1151, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France
| | - Isabelle Guichard
- Service de Médecine Interne, Hôpital Nord, CHU de Saint-Étienne, Saint-Étienne, Paris, France
| | - Maryline Poirée
- Department of Pediatric Hematology-Oncology, Centre Hospitalier Universitaire Lenval, Nice, France
| | - Fabrice Monpoux
- Unité d'Hémato-Oncologie Infantile. Hôpital de l'Archet 2, Nice, France
| | - Philippe Touraine
- Department of Endocrinology and Reproductive Medicine, Assistance Publique-Hopitaux de Paris, La Pitié-Salpêtrière, and Sorbonne University, Pierre et Marie Curie School of Medicine, Paris, France
| | - Chantal Brouzes
- Laboratory of Onco-hematology, Hôpital Necker-Enfants Malades, Paris, France
| | - Mariane de Montalembert
- Department of General Pediatrics and Pediatric Infectious Diseases, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Emmanuel Payen
- CEA, INSERM, Université Paris-Saclay, Division of Innovative Therapies, Institut François Jacob, Fontenay aux Roses, France
| | - Emmanuelle Six
- IMAGINE Institute, Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Jean-Antoine Ribeil
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Bluebird Bio, Inc., Cambridge, MA, USA
| | - Annarita Miccio
- IMAGINE Institute, Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Pablo Bartolucci
- Univ Paris Est Creteil, INSERM, EFS, IMRB, Créteil, France.,Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Philippe Leboulch
- CEA, INSERM, Université Paris-Saclay, Division of Innovative Therapies, Institut François Jacob, Fontenay aux Roses, France. .,Genetics Division, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA.
| | - Marina Cavazzana
- Université de Paris, Paris, France. .,IMAGINE Institute, Université de Paris, Sorbonne Paris Cité, Paris, France. .,Biotherapy Department and Clinical Investigation Center, Assistance Publique Hopitaux de Paris, INSERM, Paris, France.
| |
Collapse
|
35
|
Lopinto J, Gendreau S, Berti E, Bartolucci P, Habibi A, Mekontso Dessap A. Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis. Haematologica 2022; 107:1914-1921. [PMID: 35021607 PMCID: PMC9335109 DOI: 10.3324/haematol.2021.280105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Indexed: 11/12/2022] Open
Abstract
Whether corticosteroids improve outcome in patients with acute complications of sickle cell disease (SCD) is still debated. We performed a systematic review of the literature with the aim of estimating effects of corticosteroids on the clinical course of vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) in patients with SCD. The primary outcome was transfusion requirement during hospitalization. Studies were identified by search of MEDLINE and CENTRAL database. Three randomized clinical trials (RCT) and three retrospective cohort studies (RCS) were included, involving 3,304 participants and 5,562 VOC or ACS episodes. There was no difference between corticosteroids and standard treatment regarding transfusion requirement overall (odds ratio [OR]=0.98, 95% confidence interval [CI]: 0.38-2.53) but there was a significant interaction of the study type (P<0.0001): corticosteroid therapy was associated with a lower risk of transfusion in RCT (OR=0.13, 95% CI: 0.04-0.45) and a higher risk of transfusion in RCS (OR=2.12, 95% CI: 1.33-3.40. In RCT, the length of hospital stay was lower with corticosteroids as compared with standard treatment: mean difference - 24 hours (95% CI: -35 to -14). Corticosteroids were associated with an increased risk of hospital readmission as compared with standard treatment, in RCT, RCS, and the entire cohort: OR=5.91, 95% CI: 1.40-24.83; OR=3.28, 95% CI: 1.46-7.36 and OR=3.21, 95% CI: 1.97-5.24, respectively. Corticosteroids were associated with reduced number of transfusions and length of stay in RCT but not in RCS, with more rehospitalizations overall. Additional RCT should be conducted while minimizing the risk of re-hospitalizations.
Collapse
Affiliation(s)
- Julien Lopinto
- AP-HP, Hopitaux Universitaires Henri-Mondor, Service de Medecine Intensive Reanimation, F-94010, Creteil, France; Univ Paris Est Creteil, CARMAS, Creteil, F-94010, France.
| | - Segolene Gendreau
- AP-HP, Hopitaux Universitaires Henri-Mondor, Service de Medecine Intensive Reanimation, F-94010, Creteil, France; Univ Paris Est Creteil, CARMAS, Creteil, F-94010, France
| | - Enora Berti
- AP-HP, Hopitaux Universitaires Henri-Mondor, Service de Medecine Intensive Reanimation, F-94010, Creteil, France; Univ Paris Est Creteil, CARMAS, Creteil, F-94010, France
| | - Pablo Bartolucci
- Univ Paris Est Creteil, INSERM, IMRB, FHU SENEC, Creteil, F-94010, France; Univ paris Est Creteil, Centre de reference des Syndrome drepanocytaire Majeurs, Unite des Maladies Genetiques du Globule Rouge (UMGGR)
| | - Anoosha Habibi
- Univ Paris Est Creteil, INSERM, IMRB, FHU SENEC, Creteil, F-94010, France; Univ paris Est Creteil, Centre de reference des Syndrome drepanocytaire Majeurs, Unite des Maladies Genetiques du Globule Rouge (UMGGR)
| | - Armand Mekontso Dessap
- AP-HP, Hopitaux Universitaires Henri-Mondor, Service de Medecine Intensive Reanimation, F-94010, Creteil, France; Univ Paris Est Creteil, CARMAS, Creteil, F-94010, France; Univ Paris Est Creteil, INSERM, IMRB, FHU SENEC, Creteil, F-94010, France
| |
Collapse
|
36
|
Bouvarel A, Messonnier L, Derumeaux G, Bartolucci P, Boyer L, Savale L, D’humières T. Comprehensive Evaluation and Determinant of Second Lactate Threshold in Homozygous Sickle Cell Disease. Archives of Cardiovascular Diseases Supplements 2022. [DOI: 10.1016/j.acvdsp.2021.09.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Dupuy M, Saba J, Codiat R, Derumeaux G, Alassaad L, Abou Chakra L, Odouard S, Deux J, Guillet H, Savale L, De Luna G, Bartolucci P, D’humières T. Echocardiographic determinants of ventricular arrhythmia in sickle cell disease. Archives of Cardiovascular Diseases Supplements 2022. [DOI: 10.1016/j.acvdsp.2021.09.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Arlet J, Lennon H, Bailey M, Herquelot E, Lamarsalle L, Raguideau F, Bartolucci P. Association entre les crises vaso-occlusives hospitalisées et la mortalité chez les patients drépanocytaires de plus de 16 ans : une étude nationale Française. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
Tamagne M, Pakdaman S, Bartolucci P, Habibi A, Galacteros F, Pirenne F, Vingert B. Chimio-attraction des lymphocytes T CD4+ et allo-immunisation anti-globules rouges. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Tamagne M, Pakdaman S, Bartolucci P, Habibi A, Galactéros F, Pirenne F, Vingert B. Phénotypage des lymphocytes T CD4+ CXCR5+PD1+ sur sang total pour évaluer le statut d’allo-immunisation des patients drépanocytaires transfusés. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
41
|
Kiger L, Adypagavane S, Bencheikh L, Chadebech P, Pakdaman S, Hebert N, Moutereau S, Marden M, Galacteros F, Beuzard Y, Pirenne F, Bartolucci P. Dosage de l’hémolyse dans les anémies hémolytiques et le DHTR. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
42
|
Tamagne M, Pakdaman M, Bartolucci P, Habibi A, Galactéros F, Pirenne F, Vingert B. Allo-immunisation et réponses lymphocytaires T CD8+ spécifiques anti-globules rouges. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
43
|
Viret S, Floch A, François A, Malard L, Bartolucci P, Habibi A, Pirenne F. Épidémiologie de la transfusion des patients drépanocytaires de 2008 à 2018 en Ile-de-France. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
44
|
Nguyen-Peyre KA, Kiger L, Decrouy X, Vingert B, Hocini H, Lefebvre C, Bencheikh L, Chadebech P, Baudin-Creuza V, Pakdaman S, Habibi A, Pirenne F, Bartolucci P. Nouveaux mécanismes de dysfonction endothéliale dans l’hémolyse intravasculaire. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
45
|
Chadebech P, Bodivit G, Di Liberto G, Jouard A, Vasseur C, Pirenne F, Bartolucci P. Sénescence des globules rouges induite par les plasmas drépanocytaires : corrélation entre ces marqueurs et conséquence en termes d’adhérence lors des événements aigus de la maladie. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
46
|
Mansour-Hendili L, Egee S, Tarfi S, Badaoui B, De Luna G, Noizat C, Aissat A, Gameiro C, Faubert E, Picard V, Moutereau S, Makowski C, Barro C, Garban F, Jebali A, Bartolucci P, Funalot B, Galacteros F. Les anémies hémolytiques constitutionnelles de causes multiples dévoilées par le séquençage haut-débit. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Hebert N, Rakotoson MG, Bodivit G, Audureau E, Bencheikh L, Kiger L, Oubaya N, Pakdaman S, Sakka M, Di Liberto G, Chadebech P, Vingert B, Pirenne F, Galactéros F, Cambot M, Bartolucci P. Quantification de l’hémoglobine fœtale dans des globules rouges individualisés. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
48
|
Zanchetta-Balint F, Pirenne F, Michel M, Mekontso-Dessap A, Mahevas M, Guillaud C, Razazi K, Fois E, Galacteros F, Bartolucci P, Habibi A. Utilisation du Rituximab dans la prévention de l’hémolyse post transfusionnelle. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
49
|
Dupuy M, Saba J, Codiat R, Derumeaux G, Alassaad L, Abou Chakra L, Odouard S, Deux J, Guillet H, Savale L, De Luna G, Bartolucci P, D'Humieres T. Echocardiographic determinants of ventricular arrhythmia in sickle cell disease adults. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Unexplained sudden death remains one of the leading causes of death in sickle cell disease (SCD) adults. Ventricular arrhythmia is a well-known risk factor for sudden death but its prevalence and determinants in the context of SCD remain understudied.
Purpose
The aim of this study was to identify echocardiographic predictors of ventricular arrhythmia in SCD.
Methods
From January 2019 to March 2021, consecutive adult patients with SCD referred to ambulatory cardiology department for possible cardiac involvement were prospectively included (Drepacoeur cohort). All patients that had 24-hour ECG monitoring (24h-holter) and thransthoracic echocardiography (TTE) on the same day were analysed in this study. The primary end point was the occurrence of ventricular arrhythmia, defined as sustained or non-sustained ventricular tachycardia (VT), more than 500 premature ventricular contractions (PVC) on 24h-holter, or history of VT ablation.
Results
Overall, 90 patients were included and 54 (60%) were analysed. Mean age was 47.6±11.6 years (range 21–69), 53% were male. Heart function was mainly preserved with a mean left ventricular ejection fraction (LVEF) of 57.9±4.9% and a mean global longitudinal strain (GLS) of −18±2.8%. Mean tricuspid regurgitation velocity was 2.6±0.4m/s.
Ventricular arrhythmia was observed in 13 (24.1%) patients (4 non-sustained VT [range 4–121 consecutive PVC], 9 with more than 500 PVC [range 500–13000 PVC/24h] and 1 history of VT ablation). Regarding echocardiographic parameters, ventricular arrhythmia was associated with lower GLS (−15.8±1.8% vs. −19±2.7%, P<0,001), lower tricuspid annular plane systolic excursion (TAPSE, 23±5.7mm vs. 26.9±4.6mm, P=0,02) and more dilated right ventricle assessed by tricuspid annulus diameter (38.2±6.1mm vs. 34.2±4.5mm, P=0,02). In multivariate analysis, GLS was independently associated with ventricular arrhythmia (OR=2,1 CI95% [1,3; 3,3], P=0,004) with a moderate exponential correlation with PVC load on 24h-holter (R=0,5, P<0,001). Interestingly, ventricular arrhythmia was not associated with corrected QT interval nor with age or hemoglobin serum level.
Conclusion
In SCD adults with preserved LVEF, GLS was the only independent echocardiographic predictor of ventricular arrhythmia.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Dupuy
- Henri Mondor University Hospital Chenevier APHP, Physiology Department, FHU SENEC, Creteil, France
| | - J Saba
- Henri Mondor University Hospital Chenevier APHP, Physiology Department, FHU SENEC, Creteil, France
| | - R Codiat
- Henri Mondor University Hospital Chenevier APHP, Physiology Department, FHU SENEC, Creteil, France
| | - G Derumeaux
- Henri Mondor University Hospital Chenevier APHP, Physiology Department, FHU SENEC, Creteil, France
| | - L Alassaad
- Henri Mondor University Hospital Chenevier APHP, Physiology Department, FHU SENEC, Creteil, France
| | - L Abou Chakra
- Henri Mondor University Hospital Chenevier APHP, Physiology Department, FHU SENEC, Creteil, France
| | - S Odouard
- Henri Mondor University Hospital Chenevier APHP, Physiology Department, FHU SENEC, Creteil, France
| | - J.F Deux
- Henri Mondor University Hospital Chenevier APHP, Department of Radiology, FHU SENEC, Creteil, France
| | - H Guillet
- Henri Mondor University Hospital Chenevier APHP, Sickle Cell Referral Center – UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, UPEC, Creteil, France
| | - L Savale
- Bicêtre University Hospital, Assistance Publique Hôpitaux de Paris, Department of Pneumology, Kremlin-Bicêtre, France
| | - G De Luna
- Henri Mondor University Hospital Chenevier APHP, Sickle Cell Referral Center – UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, UPEC, Creteil, France
| | - P Bartolucci
- Henri Mondor University Hospital Chenevier APHP, Sickle Cell Referral Center – UMGGR, Plateforme d'expertise Maladies Rares Grand Paris Est, UPEC, Creteil, France
| | - T D'Humieres
- Henri Mondor University Hospital Chenevier APHP, Physiology Department, FHU SENEC, Creteil, France
| |
Collapse
|
50
|
Montalembert M, Voskaridou E, Oevermann L, Cannas G, Habibi A, Loko G, Joseph L, Colombatti R, Bartolucci P, Brousse V, Galactéros F. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. Am J Hematol 2021; 96:1223-1231. [PMID: 34224583 DOI: 10.1002/ajh.26286] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Accepted: 07/02/2021] [Indexed: 12/28/2022]
Abstract
Several controlled studies have evidenced good efficacy and short-term and mid-term safety profiles for hydroxyurea (HU), which has become the cornerstone for prevention of sickle-cell disease (SCD)-related vaso-occlusive crises. However, there are few large-scale reports on its long-term use and certain caregivers and patients have concerns about its safety. Following the licensing of HU in Europe for children and adults with severe forms of SCD, ESCORT-HU was designed as a Phase IV observational cohort study. It included 1906 participants, of whom 55% were adults. The most common hemoglobin (Hb) genotypes were HbSS (84.7%) and HbSβ+ (7.0%). The median duration of follow-up was 45 months, for a total of 7309 patient-years of observation. The dose of HU after 1 year was 20.6 mg/kg/d for children and 16.3 mg/kg/d for adults. There was a statistically significant decrease in the number of vaso-occlusive episodes lasting >48 h, acute chest syndrome episodes, hospitalizations, and the percentage of patients requiring blood transfusions within the first 12 months relative to the year before enrolment. Neutropenia and thrombocytopenia were the most commonly reported adverse effects. No new HU toxicity was identified. Overall, 125 pregnancies were reported in 101 women and no malformations were observed in the neonates. There were 12 pregnancies for partners of male patients treated with HU. One case of fatal myelodysplastic syndrome was reported, for which a causal association with HU could not be excluded. This cohort study of patients with SCD highlights the positive benefit-to-risk ratio of HU in children and adults.
Collapse
Affiliation(s)
- Mariane Montalembert
- Reference Centre for Sickle Cell Disease, Department of General Pediatrics and Pediatric Infectious Diseases Necker‐Enfants malades Hospital, Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Ersi Voskaridou
- Centre of Excellence in Rare Hematological Disease‐Hemoglobinopathies, Laiko General Hospital Athens Greece
| | - Lena Oevermann
- Department of Pediatric Oncology & Hematology Charité University Medicine, Berlin and Berlin Institute of Health Berlin Germany
| | - Giovanna Cannas
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Médecine Interne, Centre de Référence Constitutif: Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse Lyon France
| | - Anoosha Habibi
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐UPEC, AP‐HP Créteil France
| | - Gylna Loko
- Centre hospitalier de la Martinique Fort‐de‐France Martinique France
| | - Laure Joseph
- Biotherapy Department Necker Children's Hospital, Assistance Publique‐Hôpitaux de Paris Paris France
| | | | - Pablo Bartolucci
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐UPEC, AP‐HP Créteil France
| | - Valentine Brousse
- Reference Centre for Sickle Cell Disease, Department of General Pediatrics and Pediatric Infectious Diseases Necker‐Enfants malades Hospital, Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Frédéric Galactéros
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐UPEC, AP‐HP Créteil France
| | | |
Collapse
|